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Developmental Origins of Aggressive Medulloblastoma 
Abstract 
 
Medulloblastomas represent a heterogeneous group of cerebellar tumors that 
constitute the most frequent primary pediatric solid malignancy. Molecular characterization 
of these tumors have led to the understanding that distinct subtypes possess characteristic 
properties such as gene expression profile, histological classification, and degree of 
dissemination that are predictive of disease progression and prognosis. Fractionation of 
primary medulloblastomas has led to the appreciation of brain tumor stem cells (BTSC) that 
may be driving the more aggressive and malignant disease. However, the developmental 
origins of these cells as well as the influences of early mutations in tumor suppressors on 
development and tumorigenesis remain unclear. 
 
My work is geared towards understanding the impact of mutations in the key tumor 
suppressor genes Ptc1 and p53 on medulloblastoma formation. I first identified key 
differences in neural stem cell marker expression that distinguish between Ptc1 and Ptc1;p53 
medulloblastomas, demonstrating that the Ptc1;p53 genotype may pre-dispose to a more 
malignant, stem-like tumor. Through the use of a somatic mosaic model, we describe a 
synergistic interaction between Ptc1 haploinsufficiency and p53 deficiency leading to 
developmental seeding of the cerebellar field by pre-malignant cells and term this 
phenomenon “developmental field cancerization.” Interestingly, we observed this pre-
malignant colonization in the cerebellar stem cell compartment as well, resulting in an 
  iv 
aberrant population of self-renewing cells. Upon loss-of-heterozygosity at the Ptc1 locus, the 
Ptc;p53 animals alone develop robust cerebellar tumors that possess a definable stem-like 
population of cells that can re-initiate metastatic secondary tumors. These findings 
demonstrate how early mutations in the tumor suppressor genes, such as Ptc1 and p53, may 
lead to stem cell field cancerization and play an important role in determining future tumor 
character and prognosis.  
 
Finally, bisulfite-based mass spectrometry methylation assays were utilized to define 
differences in methylation status at various imprinted loci between BTSC and bulk tumor. 
We observed methylation differences at the KCNQ1OT1/Lit1 and CDKN1C/p57 and 
corroborated these findings with mRNA expression and RNA-FISH demonstrating bi-allelic 
expression of Lit1 in the BTSC. Through lentiviral-mediated shRNA knockdown of Lit1 in 
BTSC, I ascribe a putative role for the long non-coding RNA in maintenance of BTSC self-
renewal.  
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Chapter 1  
 
Introduction 
 
 
 
 
 
 
 
  
  2 
Introduction 
Medulloblastomas are the most common primary childhood CNS tumor, representing 16% of all 
pediatric brain tumors with about one thousand new cases every year1. The incidence of these 
cerebellar tumors is bimodal with peaks at 3-4 and 8-9 years of age2. Affected patients usually 
present with headache, vomiting, lethargy, as well as increasing head circumference secondary to 
increased intracranial pressure and obstructive hydrocephalus. The treatment of these tumors 
may be complicated by extensive local invasion, making total surgical resection difficult. 
Furthermore, craniospinal metastases, which occur in 11-43% of patients, are associated with 
significantly worse prognosis and require radiation and systemic chemotherapy, leading to 
decreased quality of life (Figure 1-1). While there have been great advances in our understanding 
of how these tumors arise as well as in development of new treatment protocols, patients with the 
most aggressive forms of medulloblastoma still have a five-year event free survival of only 30% 
and frequently suffer from iatrogenic developmental and cognitive deficits. Thus, further 
elucidation of the factors and pathways driving malignant progression could yield insights 
leading to the development of more targeted therapies and better risk-stratification.  
 
Figure 1-1 | Characteristic MRI features of medulloblastoma  
a, Sagittal T1-weighted imaging showing a cerebellar mass, typically found midline. b, Leptomeningeal 
metastases to the spinal cord is not uncommon (marked). Images obtained from Crawford et al3.  
 
  3 
In their classic review, Cushing and Bailey first proposed that embryonal rests in the developing 
cerebellum give rise to medulloblastomas, citing their early incidence as well as the 
undifferentiated cells constituting these fast-growing cerebellar tumors4. Indeed, as our 
understanding of their cellular origins has grown, it has become increasingly apparent that 
medulloblastomas arise from normal development gone awry leading to the uncontrolled 
expansion of progenitor cells, widely thought to be granule cell progenitors (GCP)5.Thus, it is 
important to begin with a basic understanding of the processes driving normal development and 
differentiation of the cerebellar organ.  
Overview of mouse cerebellar development 
The cerebellum is involved in facilitating a number of basic cognitive functions, including 
voluntary motor movement coordination, balance, equilibrium, and muscle tone (it facilitates 
muscle tone?) as well as motor learning, speech, and spatial memory5. Developmentally, the 
different cell types of the cerebellum (illustrated in Figure 1-2) arise from two distinct embryonic 
germinal zones6. The dorsomedial ventricular zone gives rise to the Purkinje cells as well as 
many of the cerebellar interneurons: Golgi, basket, and stellate cells. The rhombic lip gives rise 
to primarily the granule neurons, the most numerous cell type in the cerebellum and, indeed, in 
the entire brain.  
 
The earliest cerebellar progenitors originate from the ventricular zone at approximately 
embryonic (E) day E10.25. These cells are characterized by expression of the transcription 
factors Lhx2/9, Meis 1/2, and Irx3 and give rise to precursor Purkinje neurons by E14, which 
migrate to seed the developing cerebellar anlage6. Interestingly, Ptf1a mutations, which prevent 
generation of Purkinje cells and other GABAergic neurons in the cerebellum, result in complete 
  4 
cerebellar agenesis7, underscoring the importance of Purkinje cells and Shh-signaling in 
establishing the cerebellar field as well as driving its growth.  
 
 
Figure 1-2 | Primary cell types and basic architecture of the developing cerebellum 
Schematic representation of the early developing cerebellum adapted from Ruiz y Altaba et al8. Cell types 
derived from ventricular zone are shown in orange and red; rhombic lip derivatives are shown in shades 
of blue and indigo. Sonic Hedgehog (Shh) is secreted by the Purkinje neurons to drive the proliferation of 
the mitotically active precursor cells in the outer EGL. Post-mitotic precursors migrate inwards along the 
Bergmann glia and through the Purkinje cell layer to form the internal granule layer. The cell bodies of 
granule cells reside in the nuclear layer, also known as the internal granule layer (IGL). The Purkinje cells 
form a separate layer of cells between the IGL from the molecular layer (ML). Golgi cells, also known as 
Bergmann glia, are interspersed amongst Purkinje cells.  
 
Around E12.5, the rhombic lip gives rise to a second proliferating pool of progenitors 
characterized by expression of the basic helix-loop-helix (bHLH) transcription factor Atoh1 
(Math1), Zic1, as well as Meis1. Math1 is particularly critical for the early specification of these 
cerebellar progenitor cells6 and is also involved in cell-fate specification of inner ear hair cells9 
as well as intestinal secretory cells10. Within the cerebellum, Math1 is first expressed in the 
rhombic lip as early as E9.5 and is essential for the development of the cerebellar granule 
neurons: Math1-null animals fail to form granule cells and develop cerebellum lacking an EGL11.  
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Regulation of Math1 takes place at a number of levels and has been shown to occur 
transcriptionally by Zic112, which binds directly to a Math1 enhancer and represses its 
transcription, and post-translationally via the Bmp-pathway, which modulates Math1 protein 
stability13. Significantly, deletion of Math1 in the developing cerebellum disrupts granule cell 
proliferation and induces differentiation as well as prevents formation of tumors in a Shh-driven 
mouse medulloblastoma model14. Over-expression of Math1 similarly leads to a smaller, less 
foliated cerebellum likely through pre-mature differentiation of GCPs15, emphasizing the 
importance of maintaining appropriate levels of Math1 expression for normal differentiation and 
production of granule cell progenitors.  
 
These Math1-positive cells subsequently migrate out of the rhombic lip and coat the surface of 
the developing cerebellar field to form the external granule layer (EGL). At this point, some of 
the post-mitotic precursors will continue to migrate inwards past the Purkinje cell layer to form 
some of the cerebellar nuclei, while the vast majority of these rhombic lip derivatives will remain 
to form a zone of proliferating granule cell progenitors in the outer EGL to give rise to the 
cerebellar granule cell16. This large, clonal expansion begins at approximately postnatal day 2 
(P2) and continues until P15, and occurs secondary to secretion of the mitogen Sonic hedgehog 
(Shh)17. The primary source of Shh at this time is the Purkinje neuron, which actively secretes 
Shh in the developing cerebellum. Binding of Shh to its 12 transmembrane receptor, Ptc1, results 
in dissociation of Ptc1 from the seven transmembrane G-protein-coupled receptor-like protein 
Smoothened (Smo) and subsequent de-repression of the Shh signaling pathway (Figure 1-3)18. 
Activation of the Shh signaling pathway leads to activation of the zinc finger proteins Gli1 and 
Gli2 and inactivation of the transcriptional repressor Gli3, which together go on to drive granule 
  6 
cell proliferation17. By the end of the second postnatal week (P14), granule cell progenitors will 
finish their proliferative cycle, down-regulate Math1, and exit the cell cycle13. As this occurs, 
post-mitotic granule cells will move inwards from the EGL along the radial fibers of the 
Bergmann glial cells, pass through the Purkinje cell layer, and form the mature inner granule 
layer (IGL).  In this way, normal cerebellar development is usually considered complete by the 
third postnatal week (P21).  
 
Figure 1-3 | Schematic of the SHH signaling pathway 
In the absence of Shh, Ptc binds and prevents Smoothened-mediated activation of the Gli transcription 
factors. Binding of Shh by Ptc releases Smo, allowing activation of the nuclear translocation of the Glis 
which activate the downstream effectors of the Shh pathway. Suppressor of Fusion (SUFU) normally 
binds and facilitates the degradation of Gli. Stars denote proteins found to be mutated in 
medulloblastomas. Figure adapted from Roussel and Hatten5.  
 
 
Underscoring the importance of Shh-signaling in regulating cerebellar development and 
medulloblastoma tumorigenesis, approximately 30% of human medulloblastomas demonstrate 
deregulation of the Shh-pathway2. Moreover, genetic changes are frequently observed within 
Shh-pathway genes such as inactivating mutations in Suppressor of fusion (SUFU)19, Ptc120, 
activating mutations in Smo21, as well as copy-number gains in MYCN and Gli222. Additionally, 
the final granule neuron differentiation and migration steps of cerebellar development are 
facilitated by expression of the chemokine receptor CXCR423 and a number of proteins involved 
  7 
in glial-guided migration. CXCR4 (CD184) signaling is expressed not only in the immune 
system, where it is involved in lymphocytic chemotaxis, but also in the central nervous system24. 
The importance of CXCR4 in human tumorigenesis has been substantiated by the appreciation 
that medulloblastomas expressing high levels of CXCR4 are associated with worse prognosis25 
and small molecule antagonists of CXCR4 inhibit intracranial tumor growth26. In mice lacking 
CXCR4, GCPs have been observed to migrate prematurely along the Bergmann glia and thus 
decrease the proliferative expansion of these cells in the EGL. Conversely, mouse models that 
slow or prevent the migration of GCPs along the Bergmann glia through alteration of factors 
involved in glial cell interaction such as BDNF27 and Astn128 have been shown to lead to ectopic 
proliferative rests of GCPs that persist in the EGL beyond normal development. These 
populations of developmentally arrested cells may in fact be similar to those rests found in the 
cerebellum of Ptc1-mutant mice which frequently develop medulloblastomas29.  
Timing of human cerebellar development 
In contrast to the mouse, where the proliferative expansion of the EGL occurs largely postnatally, 
the human cerebellum undergoes a 5-fold volumetric expansion between weeks 24-40 of 
gestation. Formation of the EGL, marked by the initiation of cerebellar foliation, occurs between 
weeks 20-30 and GCP proliferation and migration take place between weeks 30-40.  The EGL 
diminishes following birth throughout the first postnatal year as the IGL continues to increase in 
volume30.  
Molecular characterization of medulloblastoma 
The term medulloblastoma refers to a type of cerebellar tumors that occur primarily during 
childhood1. Over the years since their initial characterization, it has become clear that this term 
describes a heterogeneous class of tumors that may be characterized by a number of factors that 
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are associated with variable prognoses: time of incidence, histopathology, and gene expression 
profiles31. Tumors occurring earlier during infancy (<3 years of age) are associated with 
particularly poor prognoses. Relatively few adults (>16 years of age) develop medulloblastomas, 
accounting for only 3-4% of primary intracranial malignancies overall.  
 
Histologically, medulloblastomas may be classified into three categories: classic, desmoplastic, 
and anaplastic (Figure 1-4)1. Classic medulloblastomas constitute approximately two thirds of all 
cases and are characterized by relatively uniform sheets of undifferentiated cells with high nuclei 
to cytoplasm ratios. Desmoplastic medulloblastomas in contrast have collagen fibers and stroma 
between tumor cells, and generally have fewer mitotic figures, indicating a less proliferative 
tumor-type than the classic. Anaplastic tumors are the least common and consist of highly 
mitotic and undifferentiated cell types that can be particularly resistant to current treatment 
modalities.  
 
Figure 1-4 | Medulloblastoma can present as different histological subtypes 
Representative sections demonstrating microscopic findings for the different histological subtypes of 
medulloblastoma. Desmoplastic tumors are typically associated with a Shh gene signature and large cell 
anaplastic tumors are associated with the worst prognoses. Images taken from MedScape.  
  
The greatest leap in our understanding of medulloblastoma biology came with our ability to 
perform high-throughput genome and expression analyses as a means of profiling the molecular 
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characteristics of these tumors31. These studies were paramount for elucidating key signaling 
pathways essential for tumor establishment and maintenance as well as for identifying potential 
driver mutations in tumor formation. As a result, it is now accepted that medulloblastomas may 
be sub-divided into four groups based on mRNA expression profiles: Wnt, Shh, Group C, and 
Group D2. Mutations in Wnt and Shh pathways usually occur mutually exclusive of one another 
and lead to tumors with distinct gene expression patterns. Together, Wnt and Shh tumors account 
for nearly 40% of all medulloblastomas. Group C and D tumors, known also as non-WNT/SHH 
tumors, are characterized by over-expression of genes involved in neuronal development such as 
phototransduction and glutamate signaling genes in Group C and semaphorin and beta-
adrenergic signaling genes in Group D. Group C tumors are distinct in that they also often 
exhibit amplification of the oncogene MYC and are most frequently associated with an 
anaplastic histologic presentation and disseminated disease phenotype, resulting in the worst 
prognoses of all tumor subgroups. While therapy has remained essentially identical for all 
subgroups of medulloblastoma until now, the findings from these studies inspired the 
development of novel mouse models for medulloblastoma that are allowing increased 
understanding of the differences between medulloblastoma subtypes as well as development of 
more targeted therapies and treatment protocols that are simultaneously more efficient and less 
destructive than existing modalities.  
 
Mouse medulloblastoma models for Shh-type tumors 
Human medulloblastomas with a Shh gene signature represent the best studied of the tumor 
subtypes and our understanding of these tumors has benefitted tremendously from the 
development of murine models for the disease. The initial observation that patients with Gorlin’s 
syndrome, a hereditary autosomal dominant disease associated with inactivating mutations in the 
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Ptch1 gene32, are at increased risk for developing  a number of malignancies including basal cell 
carcinoma and medulloblastomas led to the observation of Ptch1 mutations in sporadic human 
medulloblastomas20 as well as the development of one of the first mouse medulloblastoma tumor 
models 33.  
 
The long latency and low penetrance of medulloblastoma formation in the Ptch1-mutant 
animals33 implied that additional genetic lesions were required for malignant progression. It was 
observed that crossing Ptc1+/- mice with p53-deficient mice significantly increased 
medulloblastoma incidence to 95% with increased kinetics as well34. The transcription factor 
Trp53 (p53) has been shown to play a role in suppression of tumorigenesis in a wide range of 
malignancies. While p53 gene mutations are only infrequently observed in human 
medulloblastoma35,36, it should be noted that their presence is associated with universally poor 
prognosis37 and people with Li-Fraumeni syndrome, caused by germ-line mutation of p53, are at 
increased risk for developing medulloblastoma38. Additionally, mutations in the protein 
phosphatase WIP1, a known negative regulator of p53 activity, have been observed in primary 
medulloblastoma samples as well as cell lines39. More recently, amplification and over-
expression of the ubiquitination factor UBE4B has been observed in human medulloblastoma 
tumors and shown to negatively regulate the stability and function of p5340. Thus, modulation of 
p53 pathway activity remains an important aspect of medulloblastoma biology to be further 
studied. 
 
Histological examination of the cerebellum in Ptc1-mutant animals identifying ectopic 
proliferative rests in the EGL first suggested that stalled granule cell progenitors may be the 
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tumor-initiating cell-of-origin in medulloblastoma29. These findings have led to numerous mouse 
models that focused on genes involved in the Shh-signaling pathway41 and ultimately to the 
development of small molecule inhibitors of Smo that were able to suppress and delay tumor 
formation in transplantation and mouse medulloblastoma models42,43. A recent patient case study 
demonstrated that Smo-antagonists were remarkably effective at alleviating the tumor burden44,44. 
However, in this case, remission was only transiently achieved before the recurrence of 
insensitive tumor cells44,45, underscoring the need for the development of better targeted 
therapeutics as well as for the elucidation of pathways important for maintenance of treatment-
resistant medulloblastoma cells.  
Brain tumor stem cells 
In the course of normal development, pluripotent embryonic stem (ES) cells undergo 
differentiation into committed cell lineages, giving rise to the different tissues and organs of the 
body. In doing so, they lose the fundamental characteristics that define them as stem cells: the 
ability to continually self-renew and give rise to multiple lineages. At the same time, small 
populations of stem cells continue to persist in the adult that are critical for such functions as 
tissue maintenance and regeneration. Thus, it is easy to see how homeostatic maintenance of this 
subpopulation of cells is critical for not only normal development but also the continued 
maintenance of functionality throughout life. Conversely, transformation of a multi-potent and 
self-renewing cell could lead to malignancies with increased plasticity, heterogeneity, and 
resiliency, an idea forming the basis of the cancer stem cell model for tumorigenesis46.  
 
Cancer stem cells were first identified in leukemia in 199447 and have since been observed in a 
variety of solid tumors. Early transformation of a more stem-like cell could have broad 
  12 
implications on the characteristics of the subsequent tumor. For example, work within a mouse 
model for T-ALL utilizing the Sleeping Beauty transposon mutagenesis system has shown that 
altering the timing of mutagenesis along T-cell development affects the kinetics of disease 
progression, the number and distribution of driver mutations, as well as the gene expression 
profiles of the resulting tumors48. Furthermore, the conferral of properties affiliated with normal 
tissue stem cells, such as slower cell cycle rate, enhanced DNA damage repair ability, and the 
expression of multidrug efflux pumps makes tumors with a defined cancer stem cell 
compartment more refractive to conventional radiation and chemotherapeutic treatment 
regimens49,50. Thus, the functional characteristics defining a cancer stem cell can be seen as 
possessing the normal stem cell properties of self-renewal, the ability to indefinitely generate 
copies of itself, multipotential differentiation, the capacity to give rise to more differentiated cell 
types, as well as the additional property of being able to seed and initiate tumorigenesis51.  
 
Self-renewing multipotent neural stem cells were first appreciated in rat embryonic cortex52.  It 
has more recently been appreciated that multi-potent, self-renewing neural stem cells exist in the 
adult brain53 and indeed can be isolated from the postnatal cerebellum54. It should be noted here 
that Shh has been shown to be important for driving proliferation and maintenance of self-
renewal in the neural stem cells of the postnatal and adult brain55. Furthermore, p53 has been 
observed to be involved in suppression of self-renewal in normal adult neural stem cells56 as well 
in medulloblastoma stem cells through interaction with Gli1, the downstream effector of the Shh-
signaling pathway57. Thus, these cells represent a potential substrate for transformation that 
could lead to tumors with stem-like characteristics.  
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This property was first observed within a defined subpopulation of cells in medulloblastomas 
expressing CD133 (Prominin-1) as a positive surface marker, allowing their fractionation58. 
CD133+ cells can self-renew in vitro through forming non-adherent neurospheres and express 
known neural stem cell markers and genes. Moreover, these cells from primary human 
medulloblastomas could initiate tumors when transplanted back into immuno-compromised 
animals. The histopathology of the xenotransplanted tumor recapitulates the heterogeneous cell 
types of the original human brain tumor, implying multi-potency. Importantly, CD133- cells 
from the same tumors were unable to re-initiate tumors even when injected in much greater 
numbers58. High level of CD133 expression was also found to be associated with poor prognosis 
in human medulloblastomas59.  
 
CD133 surface expression has subsequently been utilized as a means of prospectively isolating 
cerebellar stem cells from the normal postnatal cerebellum in mice54. Further studies utilizing 
xenograft assays and mouse medulloblastoma models have shown that brain tumor stem cells 
(BTSCs) may localize to a perivascular niche similar to normal neural stem cells60 and can be 
radio-resistant as well61. It should be noted that parallel studies initiated within the Ptc1-mutant 
mouse model have proposed CD15 (SSEA1), another known neural stem cell marker62, as an 
alternate marker for identifying self-renewing, multipotent, tumor-propagating cells associated 
with poor prognosis in medulloblastomas63,64. These studies have laid the groundwork for 
carefully investigating and understanding this sub-population of medulloblastoma tumor cells 
that may represent the driving force behind the formation of more aggressive and treatment 
refractory tumor-types.  
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Potential origins of medulloblastoma brain tumor stem cells 
In spite of the GCP representing a potential cell-of-origin, the alternate developmental origins of 
the medulloblastoma tumor-initiating cell remain elusive. As noted previously, the cerebellum 
primarily originates from two independent germinal zones: the rhombic lip, giving rise to the 
external granule layer, and the ventricular zone. Mouse models for medulloblastoma have until 
recently always pointed towards the expansion of a granule cell progenitor as being integral for 
tumor formation. Mutations within Shh-pathway genes, such as Ptc1, SUFU, Smo, MYCN, as 
well as Shh-independent genes such as Rb, p53, Ink4d, Lig4 all lead to medulloblastomas with 
gene expression patterns consistent with the GCP as the cell of origin41,65. Moreover, acquisition 
of a GCP-identity, defined by expression of Math1, is an essential step towards tumorigenesis 
regardless of the timing of Shh-pathway activation in many of these models66,67. Lastly, deletion 
of Math1 abrogates the ability of the cerebellum to effectively generate granule neurons and 
prevents medulloblastoma formation14. However, given that cells in the EGL represent 
committed progenitors with limited capacity for self-renewal and multi-potentiality, many 
questions remain regarding how these cells may acquire more stem-like properties through 
tumorigenesis.  
 
An alternative to a progenitor cell acquiring stem-like properties is for transformation to take 
place directly within a tissue stem cell compartment. A number of labs have the taken the 
approach of enriching for self-renewing cerebellar stem cells through tissue culture and ex vivo 
transforming these cells through either inactivation of the tumor suppressors Rb and p5368 or 
activation of Myc69,70. Transplantation of the transformed cells has led to aggressive cerebellar 
tumors that express a gene signature distinct from GCP-derived medulloblastomas and, in the 
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case of Myc activation, is consistent with the Group C subtype. Even so, the exact developmental 
origin of these cerebellar stem cells is as yet unclear in spite of studies utilizing a number of 
different neural stem cell markers. CD133+ cells have been observed in the white matter54 and 
Sox2+ cells in the Bergmann glia68,71 of the postnatal cerebellum. Whether the culture-based 
purification for self-renewing cells is isolating these cells or if transformative events may 
actually occur within these cell types in the endogenous developmental context remains to be 
determined.  
 
It is worthwhile mentioning, however, that an alternative medulloblastoma cell of origin has 
been identified for the Wnt-type tumors through the observation that Beta-catenin (Ctnnb1) 
mutant animals gave rise to cerebellar tumors that originate from the dorsal hindbrain rather than 
the EGL. These tumors are both anatomically and molecularly distinct from the other subtypes of 
medulloblastoma72. Given that Wnt-type tumors represent the most easily treated 
medulloblastoma with the best prognosis of the four subtypes, it is my belief that the actual 
endogenous source of medulloblastoma BTSC driving aggressive disease has yet to elucidated. 
Epigenetic regulation of brain tumor stem cells 
Epigenetic modifications refer to heritable changes to the genome that do not involve alterations 
of the underlying nucleotide sequence. Through covalent modifications of DNA as well as of 
histones in response to both internal and external cues, regions of the genome can be made 
available for transcription or silenced by epigenetic mechanisms73,74. The significance of these 
pathways in modulating normal development as well as tumor formation has become 
increasingly appreciated. Within medulloblastoma, tumor-specific methylation changes have 
been identified in key developmental pathways75 and genetic analyses in primary tissue samples 
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have observed that a significant number of tumors contain inactivating mutations within a group 
of histone modifying enzymes76. The lack of overt karyotypic differences between CD133-
positive and CD133-negative tumor cell populations77 suggests that the switch that distinguishes 
stem from non-stem programs in a transformed cell may exist not on the level of genetics, but 
through dissimilarities in gene expression and regulation. 
 
The contribution of epigenetic regulation to both normal and malignant stem cell maintenance 
has been exemplified by work on the polycomb protein Bmi1. A component of the polycomb 
repressor complex 1, Bmi1 has been shown to be essential for normal cerebellar development 
through promoting neural stem cell self-renewal78. Bmi1 knockout induces ataxic gait and 
balance disorders in mice with a severely reduced cerebellum size. Bmi1 over-expression has 
been described in a substantial fraction of human Shh-medulloblastomas and shown to be 
required for the formation of tumors in murine models79. Interestingly, Bmi1 has been to shown 
to directly interact and cooperate with Dnmt1 in gene silencing80,81, bringing together two 
distinct mechanisms of epigenetic regulation. Needless to say, the mechanisms by which 
homeostatic regulation of stem and progenitor populations occurs remain an area of active study. 
Research objectives   
First, in order to better understand the early influences of tumor suppressor heterozygosity and 
interactions between tumor suppressor gene mutations on cerebellar development and 
progression towards malignancy, we conducted studies involving the injection of disease-prone 
embryonic stem cells carrying Ptc1+/- and Ptc1+/-;p53-/- mutations (hereon referred to as Ptc1 and 
Ptc1;p53 respectively) into wild-type blastocysts to generate somatic mosaic mouse 
medulloblastoma models. Our observations from these initial experiments laid the groundwork 
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for appreciating how developmental field cancerization of the cerebellar field by Ptc1-mutant 
cells predisposes an animal for future cerebellar malignancy and identified Ptc1 loss-of-
heterozygosity as a necessary genetic event for tumorigenesis.  
 
Having identified a unique population of aberrantly self-renewing cells in the Ptc1;p53 
developing cerebellum and tumor, we then sought to determine if mutations in Ptc1 and p53 
collaborate in their formation. I observed Ptc1 haploinsufficiency synergizing with p53 
deficiency to facilitate the complete colonization of the cerebellar stem cell compartment as well 
as to allow the aberrant persistence of this self-renewing cell population within the pre-malignant 
cerebellum. These self-renewing cells are similarly unique to the Ptc1;p53 tumors alone and 
capable of re-initiating robust secondary tumors with a disseminated phenotype. These 
observations are consistent with identification of a brain tumor stem cell arising through the 
expansion and malignant transformation of an endogenous tissue stem cell. In seeking to define 
the developmental origins of the self-renewing cerebellar stem cells through the use of a Sox2-
reporter animal, I’ve established Sox2 as a definitive marker for prospective isolation and 
characterization of the self-renewing tissue stem cell within the normal cerebellum and as a 
putative marker for brain tumor stem cells within these tumors.  
 
In Chapter 3, I go on to ask whether distinct epigenetic states at the level of DNA methylation 
exist between the brain tumor stem cell compartment and the bulk tumor, and identify coordinate 
differences in the promoter methylation of the long non-coding RNA KCNQ1OT1 (Lit1), and 
Cdkn1c (p57). These changes were functionally corroborated at the level of mRNA expression as 
well as through RNA-fish experiments demonstrating bi-allelic expression of Lit1 in the brain 
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tumor stem cell compartment. Lentiviral-mediated delivery of shRNA constructs was used to 
characterize the significance of Lit1 over-expression in brain tumor stem cells wherein 
knockdown of Lit1 leads to decreased BTSC self-renewal.  
 
The significance of these studies and future directions will be reviewed in the final chapter.  
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Chapter 2  
 
p53 deficiency facilitates developmental field cancerization 
preceding malignancy 
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Introduction 
Cerebellar development is unique within the CNS given that a significant portion of it occurs 
postnatally. Transformation occurring during this critical developmental window, characterized 
by extensive cellular proliferation, differentiation, and migration, leads to medulloblastoma, the 
most common pediatric brain tumor. Within medulloblastoma, it has become appreciated that 
distinct cells of origin exist66,70,72 and that directed initiations of tumors from these alternate 
cellular origins confer characteristic gene expression signatures, histological presentations, and 
are associated with variable patient prognoses2,82. These observations have often relied upon 
genetic disruption of key tumor suppressor gene pathways such as Rb, p53, and Ptc1, or ectopic 
activation of known oncogenes such as Myc, Smo, and Ctnnb1 within pre-determined cell 
lineages10,33,34,69,70,72,83,84, such that a tumorigenic state is abruptly induced and broadly 
distributed across the targeted organ.  Thus, while these studies have identified key driver 
mutations and pathways that are necessarily disrupted in the process of tumorigenesis, the 
importance of earlier events that may occur prior to complete pathway deregulation, such as the 
effect of the loss of the first tumor suppressor allele on cerebellar development and disease 
susceptibility, remains not well understood. Indeed, reduced allelic expression of the Wnt 
pathway tumor suppressor APC in the absence of other insults is associated with elevated colon 
cancer risk and non-random allelic loss85. In addition, epigenetic modulation precedes Wnt 
pathway activation in human colorectal cancers86. The extent to which graded expression of such 
morphogenic tumor suppressors, prior to complete loss of function, may facilitate tumor 
initiation within committed tissue stem or progenitor cells and thus alter disease predisposition is 
unclear.  
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Representing nearly 30% of medulloblastomas, Sonic hedgehog (Shh)-responsive tumors are 
primarily thought to arise through the expansion of granular cell progenitors66. Interestingly, 
incidence of Shh-responsive medulloblastomas exhibits a bimodal distribution wherein tumors 
occurring during infancy differ significantly from adult medulloblastoma in gene expression 
pattern and clinical presentation2. Similarly, while Ptc1 mutations are associated with 
desmoplastic medulloblastomas in humans and mice2,33, mutations within p53, associated with 
increased tumor grade and relapse in human medulloblastoma patients37, also significantly 
increase tumor penetrance and kinetics in Ptc1+/- mice34. Consistent with possessing a GCP cell 
of origin, both Ptc1+/- and Ptc1+/-;p53-/- (hereafter referred to as Ptc1 and Ptc1;p53, respectively) 
medulloblastomas have been previously described as having similar expression patterns as each 
other and exhibiting Shh-dependency42,43,65. Even so, while small-molecule inhibition of Shh-
pathway activity dramatically reduced metastatic tumor burden in a patient, the occurrence of 
relapse in both human44 and mouse models45 points toward the existence of an unappreciated 
cellular reserve that is independent of Shh and capable of re-initiating tumorigenesis.  
 
Disseminated tumor growth, a marker of particularly poor prognosis and aggressive 
medulloblastoma, has recently been shown to be inducible from both Ptc1 and p53 mutant 
backgrounds87. Moreover, metastatic human medulloblastomas share gene expression profiles 
with the early postnatal murine cerebellum88 during a time when multipotent cerebellar stem 
cells as well as GCPs are present54. Consistent with a cancer stem cell model for 
medulloblastomas, elevated levels of CD13359 and CD1564 (also known as Lewis X antigen and 
SSEA1) stem cell markers have been associated with poor prognosis, and murine models for the 
most aggressive medulloblastoma subtype have recently been generated through forced 
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overexpression of Myc within cerebellar stem cells isolated from p53-deficient animals69,70. 
However, the endogenous context by which malignant transformation of a tissue stem cell occurs 
remains to be elucidated.  
 
Here we show that a genetic interaction between the Ptc1 and p53 transforms cerebellar stem 
cells during development and leads to an aggressive tumor with stem-like characteristics that are 
not seen in Ptc1-deficient medulloblastomas with functional p53. Using somatic mosaic models 
of medulloblastoma, we ascribe synergism between haploinsufficiency of Ptc1 combined with 
p53 loss that causes an unexpected and fully penetrant developmental seeding of the cerebellar 
field as well as the cerebellar stem cell field. This pre-malignant cancerization of the stem cell 
field results in aberrant, persistent tissue stem cells and tumors bearing a unique population of 
tumor-initiating cells expressing both cerebellar stem and granule cell progenitor markers. 
Through orthotopic transplantation, we found this population capable of generating robust 
cerebellar tumors with metastatic properties. These data support a model wherein developmental 
cancerization of a tissue stem cell field observed within the Ptc1;p53 genotype profoundly 
influences the character of the tumor that is eventually formed. 
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Results 
Aggressive, diffuse medulloblastomas arise from a mutant developmental field 
While conditional genetic models give rise to highly penetrant and rapidly inducible tumors, 
these approaches may overlook important key developmental events that occur prior to overt 
tumorigenesis. Furthermore, given that the majority of human medulloblastomas arise from de 
novo somatic mutations, early interactions between wild-type and mutant cells may be 
particularly important in facilitating tumorigenesis. Thus, in studying the role of Ptc1 and p53 
tumor suppressors in cerebellar development and medulloblastoma formation, we utilized a 
somatic mosaic approach that establishes an in vivo competition between the wild-type and 
mutant ES genotypes, enables cell marking for lineage tracing experiments within the brain89, 
and is amenable to generating developmentally synchronized mutant and control cohorts. To 
achieve this, we injected disease-prone embryonic stem (ES) cells with Ptc1lacZ/+, p53-/- or 
Ptc1lacZ/+;p53-/-  (abbreviated as Ptc1, p53, and Ptc1;p53, respectively) genotypes into wild-type 
blastocyst to generate chimeric animals (illustrated in Figure 2-1) as a means of assessing the 
developmental and tumorigenic potential of cells carrying these mutations.  
 
 
Figure 2-1 | Establishing a somatic mosaic model for medulloblastoma 
Schematic illustrates the process by which disease-prone ES cells are derived from animals and utilized 
for production of somatic mosaic animals. 
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We observed that chimeric Ptc1 and Ptc1;p53 animals were able to recapitulate tumor histology, 
kinetics, and incidence seen in bred animals. Interestingly, while no differences in gene 
expression have been previously described between these two medulloblastoma models, we 
immediately noticed differences in the histological presentation of the tumors: Ptc1 chimeras 
usually showed focal lesions that displace adjacent folia whereas Ptc1;p53 chimeras tended to 
develop diffuse medulloblastomas that invade between the folia and extend over the majority of 
the outer cerebellum (Figure 2-2).   
 
 
Figure 2-2 | Ptc1 and Ptc1;p53 chimeras recapitulate tumor phenotype 
Representative hematoxylin and eosin stained sections from chimeric Ptc1 and Ptc1;p53 cerebellar tumors 
demonstrate focal Ptc1 tumors and diffuse, infiltrating Ptc1;p53 tumors. Scale bars, 2mm. The Kaplan-
Meier survival curves show chimeras recapitulate the kinetics and incidence of medulloblastoma 
formation seen in genetically bred animals. 
 
 
Expression of CD15 predicts poor prognosis in human medulloblastoma and is a marker for self-
renewal in normal and tumor-derived neural stem cells64. Moreover, it has recently been 
appreciated that expression of chemokine receptor CD184 (CXCR4), already known to be 
involved in facilitating GCP migration and proliferation24,26, defines a distinct molecular 
subgroup of Shh-driven medulloblastoma25. In looking to begin characterization of molecular 
differences, we first observed a statistically significant enrichment for cells expressing CD15 and 
CD184 in Ptc1;p53 tumors (Figure 2-3). These data are consistent with the more rapid onset and 
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increased penetrance as well as diffuse tumor presentation of Ptc1;p53 tumors representing a 
distinct and more malignant type of tumor from those found in the Ptc1 animals. 
 
 
Figure 2-3 | Ptc1;p53 tumors have elevated levels of neural stem cell markers CD15 and CD184 
Flow cytometric analyses of primary brain tumors for Ptc1 and Ptc1;p53 animals reveal a significant 
difference in the surface expression of the neural stem cell markers CD15 and CD184. 
 
While forced activation of Shh signaling is sufficient to initiate cerebellar tumorigenesis84,90, 
conflicting observations on the genetic and epigenetic status of the wild-type Ptc1 allele in Ptc1 
and Ptc1;p53 tumors have obscured our understanding of the required changes involved in 
tumorigenesis42,63,91. Resolving this discrepancy is necessary for identifying and tracking 
tumorigenic cells. We observed Ptc1 loss-of-heterozygousity (LOH) via direct measurement of 
the wild-type Ptc1 allele by qPCR in 17 of 18 Ptc1 and all 16 Ptc1;p53 tumors but not in any of 
the 11 older asymptomatic Ptc1 cerebella examined (Figure 2-4). These results support Ptc1 
LOH as a common genetic alteration underlying malignant transformation in these tumors, 
providing a marker for tumor-initiating events. 
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Figure 2-4 | Ptc1 loss-of-heterozygosity occurs in Ptc1 and Ptc1;p53 medulloblastomas 
a, Nine-month old, asymptomatic Ptc1 animals demonstrate that contribution bias of Ptc1 cells is 
independent of tumorigenesis. b, Quantification of the wild-type Ptc1 allele (Ptc1+) in end-point Ptc1 and 
Ptc1;p53 mice using qPCR demonstrates loss of Ptc1+ specifically in tumors but not paired midbrain 
samples or in cerebella of old (9 months), asymptomatic Ptc1 mice (Asy Cer). 
 
Surprisingly, we found that although the mutant ES genotype distinguished the tumor classes, 
there was no correlation between the extent of somatic contribution as assessed by coat color and 
the average endpoint age for either Ptc1 or Ptc1;p53 genotypes (Figure 2-5). Within the brain, 
variation in chimerism was detected outside the cerebellum, but tumors and cerebellar tissue 
appeared to predominantly consist of Ptc1;p53 mutant cells as assessed by Ptc1lacZ/+ expression, 
p53 genotyping, and genomic qPCR to quantify neo:gapdh copy number (Figure 2-6a). Tumors 
and cerebellar tissues were entirely comprised of Ptc1;p53 mutant cells in nearly all animals 
examined (Figure 2-6c), whereas variable contributions of Ptc1;p53 mutant cells were seen in 
liver and “midbrain” (defined in Methods). These results raised the question whether the tumor 
suppressor mutations enable cells to favorably respond to developmental patterning cues leading 
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to cerebellar contribution at the exclusion of wild-type host tissue, or if the bias in contribution is 
a consequence of tumorigenic selection.  
 
 
Figure 2-5 | Variation in body chimerism does not predict age of morbidity 
Degree of overall somatic chimerism as determined by coat color contribution is not reflective of age of 
death in either Ptc1;p53 (a) or Ptc1 (b) chimeras. 
	  
 
Figure 2-6 | Ptc1;p53 chimeras exhibit a contribution bias to cerebellar tumors	  
a, Representative X-Gal-stained whole mounts from endpoint Ptc1;p53 chimeric animals demonstrate 
preferential competitive colonization of both cerebellar and olfactory compartments (n= 16). b, Genotype 
analysis for mutant ES-derived and wild-type host derived p53 alleles shows the cerebellum and tumor 
are extensively mutant-derived (n= 5) c, Quantified genomic contribution using neo/gapdh ratios 
determined by qPCR (n=8). 
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In order to examine developmental bias independent of tumorigenesis, we initially measured 
cerebellar contribution in three-week old Ptc1 and Ptc1;p53 chimeric animals, a time when 
normal cerebellar development is considered largely complete but well before the occurrence of 
tumors in either genotype. Interestingly, the cerebella of these young animals also showed 
strongly biased contribution towards the mutant genotype as observed by lacZ expression (Figure 
2-7a, n= 5) and p53 PCR (Figure 2-7b, n=3), despite a range in overall brain and somatic 
chimerism. To parse apart the roles of Ptc1 and p53 mutations in driving colonization of the 
cerebellar field, we additionally examined three-week p53-null chimeras. Measurement of 
neo:gapdh by qPCR similarly showed 100% skewed contribution of Ptc1;p53 mutant cells and a 
significant enrichment for contribution in the Ptc1 genotype relative to cells deficient for p53 
alone (Figure 2-7c). These data are consistent with cerebellar enrichment occurring secondary to 
an increased ability of the mutant cells to respond to developmental patterning cues rather than 
tumorigenic selection and suggest that Ptc1-haploinsufficiency is driving this selection. 
 
Figure 2-7 | Ptc1 haploinsuffiency drives colonization of pre-malignant cerebellum 
Cerebella of three-week old Ptc1 and Ptc1;p53 chimeric animals are largely mutant-derived as seen by X-
gal staining (a) and gel-based PCR for the p53 alleles (b). c, qPCR copy number analysis of neo:gapdh in 
three-week chimeric cerebellum demonstrates significant enrichment of Ptc1 cells (p<0.001) and 
complete colonization by Ptc1;p53 cells (p<0.001) compared to p53 knockout chimeras. 
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To further investigate this hypothesis, we considered that colonization of the cerebellar anlage by 
Ptc1;p53 mutant cells may be due to an enhanced responsiveness to the morphogen Shh. To 
ascertain this, we looked first at surface expression of CD184, a known Shh-responsive marker, 
and observed an eight-fold increase in CD184+ cells in the Ptc1;p53 genotype relative to Ptc1, 
p53, and wild-type in three-week animals (Figure 2-8a). We also observed significantly 
increased expression of Shh pathway genes Math1, Gli1, and Gli2 at the mRNA level (Figure 
2-8b). These studies were further substantiated via an in vivo competition assay involving co-
injection of both Ptc1 and Ptc1;p53 mutant ES cells into wild-type blastocysts. In order to 
distinguish between the different mutant genotypes in vivo, we additionally marked Ptc1 ES cells 
with an eGFP reporter and Ptc1;p53 ES cells with an mCherry fluorescent reporter. Here we 
observed that Ptc1;p53 cells out-competed even Ptc1 cells in the colonization of the cerebellum 
as well as the dentate gyrus (Figure 2-8c).  
 
Given that we observed complete colonization of the cerebellar fields and elevated Shh signaling 
within the three-week Ptc1;p53 cerebellum, we now asked if Ptc1 LOH had already occurred at 
this early time-point. Weanling Ptc1 chimeras showed no evidence of LOH and Ptc1;p53 
chimeras showed only modest reduction in average copy number (Figure 2-9). Thus, loss of p53 
synergizes with Ptc1 haploinsufficiency to convey hyper-responsiveness to Shh-signaling and 
facilitate the establishment of not merely a pre-malignant field but an entire organ system poised 
for future malignancy. We found these observations to be reminiscent of field cancerization, a 
process that gives rise to polyclonal epithelial tumors often associated with p53 mutations92.  
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Figure 2-8 | Increased Shh activity in Ptc1;p53 3-week cerebella facilitates tissue colonization 
a, Expression of the cell surface marker CD184 is significantly increased in Ptc1;p53 three-week 
cerebellar tissue (n=4), over that of wild-type (n=7), Ptc1 (n=5), and p53 (n=3) by flow cytometric 
analyses. b, PCR analyses of mRNA from three-week cerebella of the indicated genotypes show 
significantly increased Math1 expression as well as elevated levels of the Shh-effectors Gli1 and Gli2 for 
the Ptc1;p53 genotype. c, Fluorescent images from double chimeras derived from both Ptc1 and Ptc1;p53 
mutant cells shows increased ability of the double-mutant cells to occupy the dentate gyrus as well as the 
cerebellum.  
 
 
 
Figure 2-9 | Ptc1 wild-type allele is maintained in weanling animals prior to tumorigenesis 
Quantification of the wild-type Ptc1 allele by qPCR in three-week old cerebella from Ptc1 and Ptc1;p53 
animals supports retention of the allele with a slight reduction detected in Ptch;p53 prior to tumorigenesis. 
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Interaction between Ptc1 and p53 facilitate cerebellar stem cell field colonization 
While Ptc1 and Ptc1;p53 tumors are widely regarded as interchangeable disease models63,65, our 
observations thus far are consistent with the Ptc1;p53 medulloblastoma representing a distinct 
and more malignant tumor-type. Recent work by others in the field have shown that cerebellar 
stem cells are potential cells of origins for aggressive medulloblastoma68-70. Moreover, 
independent roles have been ascribed to Shh signaling55 and p5356,93,94 in cell fate and self-
renewal decisions within neural stem cells. During normal cerebellar development, cerebellar 
stem cells with multi-lineage potency and functional properties of neural stem cells are abundant 
at postnatal day 7 (p7), after which time stem cell numbers diminish in the post-mitotic organ54. 
As such, we now sought to address the influence of Ptc1, p53, and Ptc1;p53 genotypes on early 
cerebellar development. To achieve this, we examined markers of tissue contribution and stem 
cell field colonization in chimeras (Figure 2-10a). 
 
As in tumor-bearing and weanling animals, developmental bias of Ptc1;p53 cells was observed 
by p7 with uniformly high contribution to the cerebellum seen across a range of brain chimerism 
where wild-type control chimeras showed distributed contribution throughout the brain without 
particular emphasis in the cerebellum (Figure 2-10b). To measure stem cell field cancerization, 
clonogenic neurosphere cultures were used to select for cells with neural stem-cell properties. 
Individual neurospheres from these low-density cultures were genotyped for host versus ES cell 
origin, which revealed 100% colonization of the stem cell population by Ptc1;p53 cells whereas 
Ptc1 cells contributed 67% and wild-type chimeras showed only 18% contribution (Figure 
2-10d). Thus, while the Ptc1 genotype drives extensive colonization of cerebellar tissue in 
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mosaic animals, the Ptc1;p53 genotype facilitates complete developmental field cancerization of 
the stem cell niche as well.  
 
Figure 2-10 | Ptc1 synergizes with p53 deficiency to drive cerebellar stem cell field cancerization	  
a, Schematic of analysis of mutant ES cell contribution to whole cerebellum and cell-type subsets. b, 
Ptc1lacZ expression in p7 chimeric brains shown by X-gal staining demonstrates a contribution bias of 
Ptc1;p53 cells to the cerebellum (dashed line) not seen in wild type ES cells expressing CAGGS-lacZ. c, 
Genotyping of clonal cerebellar stem cells (from low-density neurosphere cultures) derived from chimeric 
p7 cerebella shows elevated contribution by Ptc1 and complete colonization by Ptc1;p53 cells as 
compared to wild type ES chimeras. 
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Ptc1 and p53 loss synergize in cerebellar and tumor stem-cell self-renewal 
Persistent developmental rests that occasionally progress to tumorigenesis frequently occur in 
Ptc1 animals29,95. The stem cell field colonization seen in Ptc1 and Ptc1;p53 p7 chimeras 
prompted us to ask whether stem-like cells persist beyond the normal 3-week developmental 
window in Ptc1 and Ptc1;p53 cerebella or can be found in tumors through culturing cerebellar 
cells under clonogenic conditions. Significant but low numbers of self-renewing cells were 
detected in 12 out of 17 p53-deficient animals, whereas stem cells were absent in 100% of wild-
type controls (n=9).  In contrast, the majority of Ptc1 showed undetectable self-renewal and p53 
cerebella only modest levels (Figure 2-11a). These observations were recapitulated in adult 
animals where Ptc1;p53 tumors likewise showed a 100-fold increase in self-renewing cells 
relative to Ptc1 tumors (Figure 2-11b). Age-matched wild-type controls and asymptomatic Ptc1 
animals showed no measurable self-renewing cells in this assay (data not shown).  
 
Figure 2-11 | Ptc1;p53 animals possess aberrant tissue and tumor-derived stem cells 
a, Clonogenic Ptc1;p53 self-renewing cells are developmentally expanded and aberrantly persistent prior 
to tumor formation, and p53 cerebella show an elevated basal level of neurosphere forming ability relative 
to Ptc1 chimeras. b, Clonogenic self-renewing cells are significantly elevated in Ptc1;p53 tumors over 
Ptc1 tumors.  
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In order to functionally compare 3-week aberrant tissue stem cell with the tumor-derived stem 
cells, we looked first at CD15 and CD184 marker expression and observed a significant increase 
in cells positive for both markers in tumor versus 3-week cerebellar samples (Figure 2-12a). 
Quantitative genotyping of clonal neurospheres revealed Ptc1 LOH in all tumor-derived 
Ptc1;p53 neurospheres, but no LOH was observed in 3-week Ptc1;p53 clones (Figure 2-12b), 
supporting the idea that the up-regulation of these markers follows Ptc1 LOH and marks 
malignant progression. Accordingly, we found that Ptc1;p53 3-week cerebellar stem cells, unlike 
their tumor-derived counterparts, were unable to resist differentiation and retain high levels of 
Sox2 expression following growth factor withdrawal (Figure 2-12c). Therefore, the aberrant self-
renewing cerebellar stem cells in 3-week Ptc1;p53 animals retain differentiation capacity that 
appears diminished upon Ptc1 LOH and tumorigenesis. 
 
 
Figure 2-12 | Aberrant tissue stem cells differ from brain tumor stem cells 
a, Surface expressions of both CD15 and CD184 show significantly increased expression in Ptc1;p53 
tumors as compared to 3-week pre-malignant cerebella as assessed by flow cytometry. b, Copy number 
quantification of Ptc1+ shows retention in clonal neurospheres from 3-week animals and LOH in tumor-
derived cultures. c, 3-week clonal neurospheres retain a differentiation response and down-regulate Sox2 
following growth factor withdrawal, while tumor-derived cells maintain high levels of Sox2 in the 
absence of growth factor stimulation. 
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Ptc1;p53 tumor stem cells initiate metastatic medulloblastoma 
Mouse models of medulloblastoma have shown that different populations of neural progenitors 
or stem cells can be transformed through activation of distinct signaling pathways69,70,72,90. Given 
their gene expression profile and dependency on Shh-pathway activity, Shh-driven tumors are 
widely thought to arise through transformation of granule cell progenitors66. In contrast to these 
studies, we now sought to determine whether aberrant cerebellar stem cells or tumor stem cells 
from Ptc1;p53 animals have tumor initiating potential.  
 
To examine these functional properties, brain tumor stem cell (BTSC) lines were established 
through weekly, serial passaging of tumor neurospheres in the presence of bFGF and EGF. 
During this period of time, an 80-fold increase in clonogenic self-renewal was observed in the 
BTSC lines compared to primary cultures, as measured by quantitative limiting dilution assays 
(Figure 2-13a). Consistent with the enrichment for BTSC self-renewal activity, progressive 
increases in Sox2 levels were observed via immunofluorescence (Figure 2-13b, c). Clonal BTSC 
lines were generated from single neurospheres to demonstrate long-term self-renewing activity 
of these cells. Surface marker analyses of clonal derivatives from two independent tumor lines 
revealed considerable heterogeneity of marker expression for the neural stem cell markers CD15, 
CD133, and CD184 (Figure 2-13e). In contrast, high levels of Sox2 mRNA were observed in all 
BTSC lines. The clonal line B1 with uniformly high levels of all three markers was selected for 
comparison to primary tumors for the subsequent transplantation studies.  
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Figure 2-13 | In vitro cultures enriches for Sox2-positive self-renewing cells 
a, Neurosphere forming potential is significantly increased  (p<0.0001) in the established neurosphere 
lines over that found in primary neurospheres from tumors. Immunofluorescent staining for the neural 
stem cell markers Sox2 (red) and Nestin (green) in neurospheres derived from primary and secondary 
cultures of ptc1;p53 tumors (b, c) and clonally-derived lines (d) shows persistent Nestin expression and 
selection for increased Sox2 expression in culture. e, Surface marker analyses of long-term cultured 
medulloblastoma neurosphere lines (MB-NS) and FACS isolated single-cell subclones. Heterogeneity in 
CD15, CD133 and CD184 levels is seen among the line and subclones from tumor A whereas uniform 
high expression of all three markers was seen in the Tumor B line and subclones. 
 
Secondary tumor initiation was determined by intracerebellar injection of 5 x 104 cells via 
stereotactic surgery. Animals were observed closely until development of signs of morbidity 
before being euthanized. Consistent with elevated stem cell marker expression and self-renewal 
of culture-selected BTSC lines, median survival was significantly shorter than that found from 
comparable injections of primary tumor cells (Figure 2-14a). Animals injected with BTSC lines 
  37 
developed malignant growths in the cerebellum and often in the olfactory bulb, as shown by 
LacZ staining (Figure 2-14b). This unexpected observation was recapitulated through injection 
of primary, unfractionated tumor cells (Figure 2-14c), indicating that the disseminated tumor 
phenotype is intrinsic to the Ptc1;p53 tumors and not acquired through prolonged time in culture. 
By contrast, primary tissue from 3-week cerebellum engrafted in only 21% of recipients within 
three months, whereas 3-week culture-selected cerebellar stem cells failed to exhibit any tumor 
engraftment up to 15 weeks. Given that the 3-week cerebellum demonstrated levels of self-
renewing activity comparable to the BTSC (Figure 2-11) but Ptc1 LOH was not detectable in 
either the cerebellar tissue (Figure 2-9) or the self-renewing stem cells (Figure 2-12b), these 
results support Ptc1 LOH as a necessary event for tumorigenesis.  
 
 
Figure 2-14 | Brain tumor stem cell gives rise to rapid, disseminated medulloblastoma 
a, Kaplan-Meier tumor-free survival curves of mice injected with 5x104 cells from unfractionated 3-week 
cerebella (3W), tumors (TU), secondary clonogenic stem cells from 3-week cerebella (3W 2°), and brain 
tumor stem cell lines (BTSC). b, Sagittal sections of X-gal stained brains from BTSC xenograft injections. 
c, Both primary, unfractionated tumors as well as BTSC lines are able to give rise to cerebellar and 
disseminated disease. 
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High CD184 expression is associated with disseminated tumor phenotype 
While the observation of disseminated disease is generally associated with poor prognosis2, there 
exist few mouse models for studying disseminated medulloblastomas41. Interestingly, we noted 
that the disseminated phenotype observed in primary tumor injections could be tracked back to 
cells isolated from the same original tumor (Figure 2-15a, ‘Tumor 2’). We had earlier reported 
high levels of CD184 expression in the developing and tumor-bearing cerebellum as well as 
clonal brain tumor stem cells of Ptc1;p53 animals. Retrospective CD184 marker analyses of 
cultured cells from the injected tumors by flow cytometry revealed low marker expression in 
Tumor 1 and high marker expression in Tumor 2. Fractionation of bulk tumor cells by CD184 
surface expression did not enrich for self-renewing potential. Given the known role of this 
chemokine receptor in directing migration and driving proliferation of cerebellar progenitors96, 
these data are suggestive that high CD184 levels convey metastatic properties onto Ptc1;p53-
derived BTSC.  
 
Figure 2-15 | CD184 expression levels reflect metastatic potential 
a, Injection of unfractionated primary tumor cells from independent tumors reproducibly engraft in the 
cerebellum alone (Tumor 1) or both cerebellar and olfactory regions (Tumor 2). b, Retrospective FACS 
analyses of CD184 expression from passage 4 bulk neurosphere cultures derived from Ptc1;p53 tumors 
used for primary tissue injections in part a. CD184-hi profiles correspond to tumors that yielded locally 
metastatic secondary tumors. c, Limiting dilution clonogenicity assays show that self-renewing potential 
is not fractionated by surface expression of CD184. 
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Sox2 expression functionally defines self-renewing cerebellar stem cells from 
progenitor cells 
Mapping of gene expression data from metastatic human medulloblastoma samples onto mouse 
cerebellar development shows the greatest overlap with postnatal day 588, a time-point when 
multipotent, self-renewing cerebellar stem cells are known to exist and are readily abundant. 
While concordant gene expression profiles between Ptc1 and Ptc1;p53 medulloblastomas have 
suggested that GCP markers define these tumors, the observation of a definable, self-renewing 
population of stem-like cells led us to ask if the tumor-initiating cells in the Ptc1;p53 
medulloblastoma more closely resemble cerebellar stem cells or granular cell progenitors.  
 
The most frequently utilized marker for prospectively identifying and isolating self-renewing 
cerebellar stem cells has been the surface marker CD133, also known as Prominin-1. However, 
this approach requires simultaneous selection against numerous lineage-specific markers in order 
to achieve a significant enrichment for self-renewing stem cells. It has also been shown that a 
significant fraction of multipotent, clonogenic neural stem cells lacks expression of both CD133 
and CD15, another commonly used marker97. Even within the highly self-renewing clonogenic 
Ptc1;p53 BTSC lines, we observed significant heterogeneity for these surface markers. However, 
the transcription factor Sox2 has been shown to play a vital role in marking and maintaining 
adult stem and progenitor cells in a variety of tissues98 including the CNS99,100, and its expression 
is associated with worse prognosis in human medulloblastomas68. Within the mature cerebellum, 
Sox2-staining has been observed in the white-matter as well as in Bergmann glial cells within the 
Purkinje cell layer but little in vivo characterization has been performed68,101. Given the 
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uniformly high levels of Sox2 expression we observed in the Ptc1;p53 BTSC, we thought to test 
whether Sox2 would function as a definitive cerebellar stem cell marker.  
 
To approach this question, we utilized a previously characterized Sox2-GFP knock-in reporter 
animal98,99 and immediately observed a distinct population of GFP-positive cells constituting 
6.5% of cells within the p7 cerebella (59,98,99,102a). While concurrent surface marker analyses for 
CD15 and CD133 demonstrated a similar frequency of positive cells (6.4% and 4.9%, data not 
shown), cells expressing these neural stem cell markers were highly enriched in the Sox2+ 
fraction of the cerebellum (Figure 2-16b). In clonogenic neurosphere cultures of unfractionated 
cerebellum, we observed that all neurospheres were uniformly positive for GFP (Figure 2-16c). 
Moreover, fractionation based on GFP-marker expression permitted the absolute isolation of 
self-renewing activity within the Sox2+ fraction (Figure 2-16d); plating even 2x105 Sox2-
negative cells yielded no neurospheres in this assay (data not shown). Finally, consistent with 
GFP-fractionation separating cerebellar stem cells from granule cell progenitors and the fact that 
these two populations are thought to express distinct gene signatures, we observed 10-fold 
enrichment for Sox2 accompanied by 10-fold depletion in Math1 expression within GFP-positive 
cells as measured by qPCR (Figure 2-16e). Taken together, our data support Sox2 as a definitive 
marker for the self-renewing cerebellar stem cell within the normal, developing cerebellum and 
offers a simple yet effective approach for the further isolation and study of these cells.  
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Figure 2-16 | Sox2 marks self-renewing cerebellar stem cells in the postnatal cerebellum 
a, Analysis of dissociated cerebellar cells by flow cytometry shows an easily identifiable population of 
GFP-positive cells. b, Sox2-positive cells are enriched for expression of other neural stem cell markers. c, 
Fluorescent as well as bright-field images from low-density neurosphere culture of unfractionated and as 
well as GFP- and GFP+ cells demonstrate marked enrichment for self-renewing cells in the GFP+ fraction, 
quantified in (d). e, GFP-positive cells highly express Sox2, not Math1.  
 
Ptc1;p53 BTSC maintain Shh-signaling in spite of differentiation cues  
Having shown that within the normal cerebellum Sox2-positive cerebellar stem cells are distinct 
from Math1-expressing granule cell progenitors, we now sought to extend these observations to 
the medulloblastoma disease models by quantitative comparison of gene expressions for a small 
subset of GCP-signature genes (Math1, Gli1, and Gli2) and CbSC-signature genes (Sox2, Hes1). 
We found that GFP-fractionation of wild-type p7 cerebellum demonstrated enrichment for the 
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GCP-signature in the Sox2-negative fraction and CSC-signature in the Sox2-positive fraction. 
Consistent with a bFGF-dependent mechanism for blocking Shh-signaling and inducing GCP 
differentiation103, we observed that culturing wild-type cerebellar stem cells in the presence of 
bFGF and EGF results in abrogation of the GCP-signature but maintenance of the CbSC 
signature (Figure 2-17, left panel). Interestingly, even though Ptc1;p53 cerebella already show 
aberrant expression of GCP-associated genes, the aberrant tissue stem cells present at this time 
are not able to completely maintain high levels of these genes in the presence of bFGF (Figure 
2-17, middle panel). Remarkably, cultured brain tumor stem cells upregulated both gene 
signatures and maintained them at high levels even in the presence of a differentiating stimulus 
expected to down-regulate Shh signaling and induce cellular differentiation (Figure 2-17, right 
panel).  
 
 
Figure 2-17 | Ptc1;p53 brain tumor stem cells highly express both GCP and CbSC gene signatures 
qRT-PCR analyses for GCP and CSC gene signatures in the indicated genotypes and tissues show intact 
bFGF-dependent down-regulation of GCP signature in wild-type and pre-malignant tissue stem cells, but 
not brain tumor stem cells.  
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Give that neither Ptc1 pre-malignant cerebella nor full-blown Ptc1medulloblastoma are able to 
reproducibly self-renew or even be propagated in vitro in the presence of bFGF, we posited that 
p53 deficiency must be vital for permitting the aberrant persistence and expansion of both pre-
malignant tissue stem cells and brain tumor stem cells. While p53 has been shown to modulate 
self-renewal and differentiation in normal neural stem and progenitor cells as well as in tumor 
stem cell through both Shh-dependent and independent mechanisms57,94, its role in the 
maintenance of cerebellar stem cell maintenance of self-renewal has yet to be directly 
investigated.  
 
To approach this question, we compared p53 pathway activities between the CbSC and GCP 
populations of the p7 cerebella of Sox2-GFP reporter animals (Figure 2-18a). While we did not 
observe differences in p53 mRNA levels between these two compartments, the expression of p21, 
a cell cycle inhibitor and well-established p53 target gene, is consistent with decreased p53 
pathway activity within the cerebellar stem cell compartment. Furthermore, we found concordant 
upregulation of another p53-responsive gene: the bHLH protein Id2, which has been recently 
shown to be directly bound and repressed by p53 within neural progenitors104. Moreover, Id2 has 
been reported to interact with and destabilize Math1 in the mouse Shh-medulloblastoma model13. 
Consistent with these findings suggesting that p53-dependent and Id2-mediated modulation of 
Math1 may facilitate differentiation of cerebellar stem cells down a granular cell lineage, we 
additionally observed a significant expansion of the Sox2+ cell population in Ptc1;p53;Sox2-
GFP chimeric animals relative to wild-type Sox2-reporter animals (Figure 2-18b).  Thus, cells 
deficient in p53 may be resistant to GCP-specification and more effectively colonize the 
cerebellar stem cell compartment.  
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Figure 2-18 | Decreased p53 pathway activity may expand population of Sox2+ cerebellar cells 
a, qPCR expression analyses for p53 and two of its downstream effector genes, Id2 and p21, show 
differences in p53 pathway activity between distinct cellular compartments of the wild-type cerebellum. b, 
Flow-cytometrc analyses of GFP-positivity in postnatal day 7 cerebellum shows expansion of Sox2+ 
population in the Ptc1;p53 but not wild-type genotype.  
 
Discussion 
Field cancerization was first described in epithelial malignancies in which tumor foci were 
observed to be surrounded by a field of overtly normal pre-malignant cells92. The resulting 
malignancies were typically multi-focal and frequently associated with p53 mutation or loss105. 
Analogous to these observations and within the setting of chimeric organismal development, we 
have been able to ascribe a previously unappreciated role for Ptc1 haploinsufficiency that allows 
mutant cells to competitively and preferentially seed a susceptible organ field. Specifically, we 
have observed that both Ptc1 and Ptc1;p53 mutant cells are non-randomly targeted to 
developmental regions where Shh is known to play a key role. Contrary to the classic two-hit 
tumor suppressor model where the first-hit is considered largely inconsequential to 
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tumorigenesis106, our findings ascribe a much more ominous effect of tumor suppressor 
heterozygosity in these tumors. However, consistent with the two-hit model and definitively 
separating pre-malignant seeding from outright transformation, progression to full-blown 
malignancy within these tumors still requires the occurrence of Ptc1 loss-of-heterozygosity. As 
in field cancerization, we observed synergistic interactions between Ptc1 and p53 resulting in a 
diffuse tumor phenotype as well as increased tumor kinetics and penetrance that are suggestive 
of polyclonal disease. Thus, early Ptc1 and p53 mutations collaborate within development in a 
non-random manner to pre-dispose an animal to cerebellar tumors, a phenomenon that we are 
terming developmental field cancerization (Figure 2-19).  
 
 
Figure 2-19 | Developmental field cancerization pre-disposes to malignant transformation through 
preferential seeding of the susceptible organ 
Cartoon depicting the seeding of the cerebellar field with pre-malignant cells and the occurrence of Ptc1 
LOH leading to focal (Ptc1) and multi-focal, diffuse tumors (Ptc1;p53) with self-renewing and 
disseminated properties.  
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Surprisingly, we found that p53 deficiency in the context of Ptc1 mutation not only dramatically 
increases the rapidity and incidence of medulloblastoma formation but also fundamentally 
changes the properties of the resulting tumor. While it has been shown that ex vivo induction of 
oncogenic changes in isolated self-renewing cerebellar stem cells can lead to tumor-initiating 
cells68-70, we report here the in situ transformation of an endogenous tissue stem cell specific to 
the Ptc1;p53 cerebellum, representing a bona fide in vivo mechanism leading to malignancy. 
Through further molecular characterization of and transplantation assays involving this unique 
subpopulation, we found Ptc1;p53 medulloblastomas to be heterogeneous tumors with heretofore 
unappreciated stem-like and metastatic qualities, and defined Ptc1 LOH as the genetic switch 
allowing a pre-malignant tissue stem cell to become a tumor-initiating cell. Additionally, the 
utilization of a novel approach for marking and prospectively isolating these self-renewing 
cerebellar stem cells has allowed us to appreciate key differences in gene expression between 
mutant and wild-type cerebellar stem cells as well as to suggest a potential mechanism by which 
deficiency in p53 allows for the prolonged persistence of these cerebellar stem cells.  
 
Thus, while Ptc1 and Ptc1;p53 tumors may have been considered largely identical and 
interchangeable, we describe here within the Ptc1;p53 animals the identification of a unique sub-
population of clonogenic brain tumor stem cells that surprisingly possess properties of both 
cerebellar stem and granule progenitor cell lineages. This population may function as yet another 
putative cell of origin and drive the more malignant and aggressive disease progression (Figure 
2-20). Finally, while disseminated tumor growth has recently been proposed to arise from the 
stochastic accumulation of mutations within rare cells of the primary tumor87, our work suggests 
that developmental field cancerization within the tissue stem cell compartment may not only 
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convey many of the properties required for metastatic growth but also dramatically amplify the 
occurrence of these ‘rare’ cells within the primary tumor. Elucidating the genetic pathways 
responsible for stem cell field cancerization, shown here to presage aggressive cancers, may be 
an important means of identifying mechanisms for therapeutic intervention of treatment-
refractory tumors. 
 
 
Figure 2-20 | Ptc1 and p53 mutations interactions lead to an alternate, stem-like cell-of-origin  
Model for polyclonal tumor initiation in Ptc1;p53 medulloblastomas derived from expansion of 
an early multi-potent cerebellar stem cell.  CbSC cerebellar stem cell; GCP granule cell 
progenitor; MPP multi-potent progenitor; TIC tumor initiating cell; TPC tumor propagating cell. 
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Methods 
 
ES cell line derivation and culture 
Morula stage embryos were harvested at 2.5 dpc from superovulated females mated to 
appropriate males, and cultured in potassium simplex optimized media with amino acids 
(KSOM-AA) for two days107. The zona pellucida was removed from unhatched blastocysts with 
Acid Tyrode’s solution (Sigma-Aldrich T1788). Each blastocyst was plated in one well of a 96 
well plate on irradiated mouse embryonic fibroblast (MEF) feeders, and cultured in ES cell 
media containing 1000U/ml LIF (Millipore) and 50 uM MEK1 inhibitor (PD98059, Cell 
Signaling) for five days. Attached blastocysts were dissociated with trypsin and replated on 
MEFs in single wells of a 96 well plate. Wells containing colonies with ES cell morphology 
were expanded, genotyped, and cryopreserved. ES lines were function tested for chimera 
formation and germline potency. New lines characterized in this work include: Ptc1LacZ/+; 
p53null/null (n=3), Ptc1LacZ/+(n=2), p53null/null (n=1), wt-lacZ Z/EG (n=1). EF1a-H2BmCherry 
marked cells were generated by homologous recombination of the transgene adjacent to the 
Collagen1a locus to facilitate ubiquitous expression. 
 
Production of mouse chimeras and animal husbandry 
Chimeric mice were generated by injecting 5-10 ES cells into blastocyst stage embryos derived 
from superovulated females from CD-1 (Charles River) crosses. Embryos were isolated at day 
2.5 pc, cultured in KSOM-AA overnight, and injected as expanded blastocysts prior to transfer to 
day 2.5 pc pseudopregnant CD-1 females. The Ptc1LacZ allele was derived from line Ptc1tm1Mps/J8 
(Jackson Labs, stock number 003081); the p53 allele was derived from line 129-Trp53tm1Tyj/J31 
(Jackson Labs, stock number 002080); the wt-lacZ allele was derived from the Z/EG line102. 
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Tissue from Sox2-GFP reporter mice were obtained from the Hochedlinger lab98,99. Mice were 
bred and maintained on a 129/B6 mixed background in pathogen-free conditions at the 
Children’s Hospital Boston. All procedures were performed with Institutional Animal Care and 
Use Committee (IACUC) approval.  
 
Genotyping, expression analysis, and copy number analysis by quantitative-PCR 
Genomic DNA and mRNA for qPCR were isolated from liver (median lobe), cerebellum, tumor, 
and “midbrain” (comprising basal forebrain, thalamus, hypothalamus and the midbrain proper), 
and individual cultured neurospheres. Genomic DNA was prepared using standard isopropanol 
precipitation protocol. mRNA isolation was achieved using the Qiagen RNA Miniprep column 
preparations. Analyses were performed on a StepOnePlus machine (ABI). 
 
neo- To determine relative contribution of ES and host cells in chimeric animals, frequency of 
the neomycin resistance (neo) gene was compared to the housekeeping gene Gapdh by qPCR 
using the delta-delta CT method. Gapdh copy number was chosen as a control as it has been 
shown not to vary in p53 null tumors108. The Ptc1LacZ and p53null alleles each contain a single 
copy of neo. Genomic tail DNA from Ptc1+/+; p53+/+ (0 neo copies), Ptc1LacZ/+; p53+/+ (1 neo 
copy), Ptc1LacZ/+; p53null/+ (2 neo copies) and Ptc1LacZ/+; p53null/null (3 neo copies) mice were used 
to create a standard curve for neo copy number.  
 
Ptc1 wild-type- Frequency of the Ptc1 wild-type (WT) allele was compared to Gapdh by qPCR 
to detect loss of heterozygosity (LOH) events at the Ptc1 locus. Genomic DNA from Ptc1LacZ/LacZ 
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(0 WT copies), Ptc1LacZ/+ (1 WT copy), and Ptc1+/+ (2 WT copies) DNA isolated from ES cell 
lines were used to create a standard curve for copy number. Primers used include:  
Gapdh: 5’-ATAACGGCGGTTCATTCATT-3’, 5’-GGGCTTCTTTCTTTACTTTCG-3’ 
neo:  5’-GGATCTCCTGTCATCTCACCT-3’, 5’-ATCATCCTGATCGACAAGACC-3’ 
Ptc1:  5'-CTGCGGCAAGTTTTTGGTTG-3', 5'-AGGGCTTCTCGTTGGCTACAAG-3' 
 
Quantitative Expression Analyses – RNA isolated as described above and converted to cDNA 
using the ABI high-capacity cDNA reverse transcription kit. Expression values were calculated 
by delta-delta CT method and normalized to Gapdh. Primers used are as follow:  
 
Gapdh:  5'- GTTGTCTCCTGCGACTTCA -3’, 5’- TGGTCCAGGGTTTCTTACTC -3’ 
Gli1: 5’- TTCAAGGCCCAATACATGCT -3’, 5’- GCGTCTTGAGGTTTTCAAGG -3’ 
Gli2: 5’- GGTCTCTTGGAGGACAGCAG -3’, 5’- TCTCATGTCAATCGGCAAAG -3’ 
Hes1: 5’- ATGCCGGGAGCTATCTTTCT -3’, 5’- ACACCGGACAAACCAAAGAC -3’ 
Id2: 5’- CCGCTGACCACCCTGAAC -3’, 5’- CCGCTGACCACCCTGAAC -3’  
Math1: 5’- ACAGGTCCTTCTGTGCCATC -3’, 5’- GCTTCCTCTGGGGGTTACTC -3’ 
p21: 5’- ATGTCCAATCCTGGTGATGT -3’, 5’- TGCAGCAGGGCAGAGGAAGT -3’ 
Sox2: 5’- CCGAGGAGGAGAGCGCCTGT -3’, 5’- GCTCGAGACGGGCGAAGTGC -3’ 
p53: 5’- TGAAACGCCGACCTATCCTTA -3’, 5’- GGGCACAAACACGAACCTCAAA -3’ 
 
Histology and Xgal staining 
For H&E staining, paraformaldehyde-fixed tissues were dehydrated with an ethanol series, 
xylene, then embedded with Paraplast. 5 micron sections were dewaxed, rehydrated and stained 
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with hematoxylin-eosin. For Xgal staining, tissues were fixed in 2% paraformaldehyde, 0.2% 
gluteraldehyde for 1 hour at room temperature, washed in PBS and stained for 16-18 hours at 
20oC (Ptc1lacZ lines) or 6-8 hours at 25oC (Z/EG lines) in Xgal buffer (1xPBS, 2mM MgCl2, 
0.1% Sodium deoxycholate, 0.2% Nonidet P-40, 5 mM potassium ferrocyanide, 5 mM potassium 
ferricyanide, 1 mg/ml X-Gal). Stained tissue was washed in rinse buffer (1xPBS, 2mM MgCl2, 
0.1% Sodium deoxycholate, 0.2% Nonidet P-40) and postfixed in 4% paraformaldehyde 
overnight at 4oC. 
 
Neurosphere culture, Low-density Neurosphere formation and Clonogenicity assays  
Bulk cultures- Tissues were isolated, minced, and triturated in Accutase (Millipore) to obtain a 
single cell suspension. After centrifuging, cells were grown in neurosphere (NS) media 
consisting of DMEM/F12 supplemented with 20ng/ml of bFGF, 20ng/ml of EGF, B27 
supplement, and penicillin/streptomycin109. Bulk neurosphere cultures were passaged by 
disaggregation with Accutase and maintained in NS media.  
 
Clonal analyses- To quantify self-renewal, neurospheres were dissociated into single cells using 
Accutase, counted, and plated at 1500 cells/ml in NS media in six-well replicates. Clonal 
neurospheres were counted after two weeks. For the 96-well clonogenicity assays, limiting 
dilutions of cells were plated in replicate wells in a 96 well plate in 100µl of NS media per well. 
Wells were scored for the presence of neurospheres and the frequency of positive wells used to 
calculate the frequency of self-renewing cells using the Poisson distribution110. 
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Immunostaining 
Neurospheres were fixed with 4% PFA and 2% sucrose for 20 minutes, permeabilized with 0.4% 
Triton-X 100 for 1hr, blocked for 30 minutes with 5% normal goat serum, 5% normal donkey 
serum, 0.02% Tween-20 in Tris Buffered Saline, and incubated overnight at 4ºC in the presence 
of primary antibodies (Nestin, AbCam, 1:100; Sox2, R&D Systems, 1:1000). Washes used 
0.02% Tween-20 in Tris Buffered Saline, and secondary antibodies used were Cy2 donkey anti-
rabbit and Cy3 donkey anti-mouse (Jackson Immunoresearch, 1:500). Visualization was 
performed on a Zeiss LSM510 META 2-photon confocal microscope. For growth factor 
withdrawal analysis, cells were cultured adherently on poly-L-lysine coated wells (Sigma) for 
one week in the presence or absence of growth factors and stained as above. ImageJ was used for 
quantification of cellular staining intensity. 
 
Flow cytometry 
Tissues were dissociated into single-cell suspensions as described above for neurosphere culture. 
Cells were resuspended in PBS + 2mM EDTA + 0.5% BSA and incubated for 30 minutes with 
PE-conjugated CD15 (R&D Systems), PE-conjugated CD133/Prominin (Miltenyi), and 
Alexa647-conjugated CD184 antibodies (eBioscience). Samples were subsequently run on a BD 
LSRII system gating on live cells through excluding debris and dead cells using FSC/SSC 
parameters and 7AAD staining (BD Biosciences). Gates for marker positivity were determined 
through staining of samples with anti-mouse isotype controls (Miltenyi Biotec). Analyses were 
performed and graphs generated using FlowJo (Tree Star). Cell sorting experiments were done in 
conjunction with the HSCI/Joslin Flow Cytometry Core on the BD FACSAria.  
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Intracerebellar transplantation assays 
NCr nude (CrTac:NCr-Foxn1nu) mice (4-6 week old) were anesthetized with ketamine/xylazine 
and placed into a stereotaxic frame (Stoelting). A 1cm incision was made in the scalp and a 
Dremel drill was used to bore a hole approximately 1mm lateral and 3mm posterior to lambda. 
Primary tissues were dissociated into single cell suspensions as described above. 5x104 cells in 
2ul of PBS were drawn into a pulled glass needle and delivered into the cerebellum 3mm below 
the surface using a PicoPump (World Precision Instruments). The incision was closed using EZ 
Clips (Stoelting) and the animals monitored daily for the development of neurological symptoms.  
 
Statistical analyses 
All graphs were generated and statistics performed using Prism 5.0 (Graphpad Software). 
Statistical analyses for self-renewal and Ptc1 wild-type allele quantification were performed 
using the Kruskal-Wallis Test with Dunnett’s Multiple Comparison Test to determine 
statistically significant differences between different genotypes. Comparison of CD184 surface 
expression was performed using two-way ANOVA with Bonferroni post-tests for the different 
genotypes. CD15 surface expression was compared using Student’s t-test. Comparisons between 
survival curves were performed using the Mantel-Cox log-rank test. All experiments with error 
bars are represented as the mean ± standard error.  
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Introduction 
Treatment for medulloblastoma, and indeed cancers in general, is often complicated by tumor 
heterogeneity. Prior to the molecular characterization and understanding of the many pathways 
and genes involved in tumor formation, cancer therapy has relied upon indiscriminate treatment 
modalities that preferentially target rapidly dividing cell populations. Such therapies remain the 
current standard of care for medulloblastoma patients111. Molecular genetics has led to the 
identification of four medulloblastoma subtypes characterized by deregulation of distinct, often 
non-overlapping gene programs that respond differentially to conventional therapy2, driving the 
development of targeted therapies42-44. Indeed, continued advances in our molecular 
characterization of these medulloblastoma have led to the recent realization that intra-tumor 
heterogeneity represents yet another important aspect of tumor biology meriting careful 
investigation and consideration in the development of new treatment modalities. 
 
Within some medulloblastoma, a further definable subset of cells with stem-like character has 
been identified that are generally marked by neural stem cell markers, associated with poor 
disease prognosis, and able to give rise to robust tumors. For example, fractionation of primary 
tumors for the cell surface marker CD133 has demonstrated dramatic enrichment for tumor-
initiating capabilities in the CD133-positive fraction in human tumor samples58. The 
observations that no obvious karyotypic differences exist between CD133-positive and negative 
fractions77 as well as that fractionated CD133-negative cells demonstrate tri-lineage potential and 
the ability to regenerate CD133 marker expression are suggestive of a role for epigenetic 
regulation in the maintenance of stem-like properties in these cells97. Consistent with this 
concept, genetic analyses of human medulloblastoma samples have shown that a significant 
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fraction of tumors carries mutations in histone modifying genes and aberrancies in DNA 
methylation of key developmental and signaling pathways. Furthermore, Bmi1, a member of the 
polycomb repressive complex 1 (PRC1) involved in epigenetic gene 
silencing33,34,69,70,72,83,84,98,99,112,113, has been found to regulate normal cerebellar and tumor stem 
cell self-renewal and to be critical for tumor-initiation in mouse models. Interestingly, it has been 
shown that Bmi1 interacts with DNA methyltransferase 1 (Dnmt1)80, an enzyme required for 
maintenance of genomic imprinting and involved in gene silencing74, suggesting that significant 
functional interplay may also occur between these two epigenetic mechanisms in cerebellar 
development. Furthermore, recent observations that polycomb targets in embryonic stem cells 
are frequently found to be hypermethylated in a variety of malignancies114,115 suggest that the 
epigenetic states of stem and progenitor cells may be particularly important in pre-disposition to 
tumorigenesis. 
 
We had previously identified a unique sub-compartment of tumor-initiating cells within Ptc1;p53 
medulloblastoma tumors that possesses stem-like properties and the ability to give rise to 
aggressive, disseminated secondary tumors upon transplantation. Interestingly, these cells were 
found to express marker genes for both cerebellar stem cells as well as granular cell progenitors. 
Furthermore, we identified genetic loss-of-heterozygosity at the Ptc1 locus as necessary for 
tumorigenesis in both Ptc1 and Ptc1;p53 animals. Given that we observed Ptc1 LOH in the bulk 
tumor as well as in the self-renewing tumor-initiating stem cell compartment, we now sought to 
ask what additional epigenetic changes at the level of DNA methylation may exist within the 
BTSC population that distinguish it from the rest of the tumor. Here we show that Ptc1;p53 brain 
tumor stem cells differ from the bulk tumor tissue in promoter methylation status of the 
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imprinted genes Kcnq1ot1 and Cdkn1c. Through mRNA expression analysis and RNA-FISH, we 
observe aberrant bi-allelic expression of Kcnq1ot1 in the BTSC compartment. Finally, lentiviral-
mediated knockdown of Kcnq1ot1 leads to decreased tumor stem cell self-renewal, suggesting a 
role for the long non-coding RNA in BTSC maintenance.  
 
Results 
 
Loss of imprinting has been observed in a number of malignancies and developmental 
diseases116. Moreover, global loss of imprinting has been shown to pre-dispose to adult 
tumorigenesis in mice117. In order to begin characterization of differences in DNA methylation 
between Ptc1;p53 brain tumor stem cells (n=5) and primary tumor samples (n=5), we queried the 
methylation status of 78 imprinted genes through bisulfite-based mass spectrometry methylation 
assays that allowed us to measure the methylation state of individual CpGs in a high-throughput 
screen118. We observed that 10 of the 78 imprinted gene promoters examined demonstrated 
significant and reproducible differences in DNA methylation between the primary tumor and 
BTSC samples (data not shown, summarized in Figure 3-1), consistent with a role for DNA 
methylation in distinguishing between tumor and BTSC.  
 
Figure 3-1 | BTSC-specific changes in DNA methylation. Table cataloguing the changes in promoter 
methylation of imprinted gene loci identified between Ptc1;p53 brain tumor stem cells and Ptc1;p53 
primary tumor samples, the allele from which the genes are normally expressed, as well as the 
directionality of the methylation change in BTSC.  
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We were immediately intrigued by a set of coordinated changes identified in the BTSCs: 
simultaneous hypermethylation at Kcnq1ot1 (Lit1) and hypomethylation at Cdkn1c (p57) (Figure 
3-2a) that are consistent with loss-of-imprinting occurring within the BTSC at these loci. Mean 
methylation was decreased to less than 20% at the Kcnq1ot1 locus and dramatically increased to 
nearly 80% at the Cdkn1c locus (Figure 3-2b). The cyclin-dependent kinase inhibitor p57 plays a 
well-established roles in regulating cell cycle exit119 and its regulation is known to be involved in 
maintenance of both pancreatic as well as intestinal crypt progenitor cell populations120,121. In 
zebrafish retina, Shh-regulated activation of Cdkn1c has been shown to necessary and sufficient 
for cell cycle exit of retinal progenitor cells122. Within medulloblastoma, high levels of Cdkn1c 
are associated with Notch pathway activation and observed in the Wnt and Shh subtypes of 
medulloblastomas82.  
 
The Cdkn1c gene locus exists as part of an imprinting cluster that has been shown to be regulated 
by the expression of the 90+kb long, non-coding, and paternally expressed RNA112, Kcnq1ot1 
(Figure 3-3a). Although the exact mechanism by which Kcnq1ot1 modulates Cdkn1c promoter 
methylation remains an area of active research, it has been observed to directly bind to and 
interact with Dnmt1 in mediating silencing of Cdkn1c among other genes123.  Furthermore, 
hypomethylation in the imprint control region of Kcnq1ot1, associated with silencing of Cdkn1c 
expression, is often observed in Beckwith-Wiedemann syndrome, an overgrowth condition with 
predisposition to malignancy124. As such, it is conceivable that loss of imprinting occurring in the 
Kcnq1ot1-imprinted gene cluster in the TSC may allow the cells to aberrantly silence Cdkn1c 
expression via an imprinted gene network in order to maintain self-renewal potential and resist 
differentiation (Figure 3-3b). 
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Figure 3-2 | Coordinate changes in promoter methylation for Cdkn1c and Kcnq1ot1 are observed in 
BTSC 
a, Examination of the MassArray data demonstrates complete hypomethylation at the Kcnq1ot1 gene 
locus coupled with hypermethylation at the Cdkn1c gene locus, quantified in (b). Transcriptional start 
sites are denoted by blue arrowheads and gray boxes indicate the exons of the resulting transcript.  
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Figure 3-3 | Kcnq1ot1 modulates transcription of Cdkn1c 
a, Schematic illustrating the relationships between promoter methylation states of Kcnq1ot1 and Cdkn1c 
normally. Expression of the Kcnq1ot1 RNA and interaction with Dnmt1 has been shown to be required 
for silencing of the Cdkn1c promoter. b, Kcnq1ot1 suppression of Cdkn1c expression is a potential 
mechanism in the maintenance of BTSC. 
 
In order to see whether the observed differences in methylation are reflected at the level of gene 
expression, we examined mRNA levels for Cdkn1c and Kcnq1ot1 in primary tumor tissue as 
well as in BTSCs. Consistent with the promoter methylation status described earlier, we found 
Kcnq1ot1 expression increased by approximately 2-fold and Cdkn1c decreased nearly 10-fold in 
the BTSC relative to primary tumor tissue samples (Figure 3-4a).  Given the changes in gene 
expression, we hypothesized that loss-of-imprinting had occurred within the BTSC lines 
involving bi-allelic activation of the Kcnq1ot1 RNA expression. Indeed, we observed bi-focal 
punctate localization of the Kcnq1ot1 RNA within the majority of BTSC examined but not in 
primary tumor cells (Figure 3-4b, c). These findings are consistent with our previous observation 
that approximately 1 in 3 brain tumor stem cells but only 1 in 500 primary tumor cells are 
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capable of in vitro self-renewal (Figure 2-13a, data not shown). Thus, methylations changes at 
the Kcnq1ot1/Cdkn1c gene loci observed in the BTSC are associated with coordinate changes in 
RNA expression levels and enriched for in a purified population of self-renewing, tumor-
initiating stem cells. 
 
Figure 3-4 | Bi-allelic expression of Kcnq1ot1 and silencing of Cdkn1c is specific to BTSC 
a,  qPCR quantification of Cdkn1c and Kcnq1ot1 transcripts in Ptc1;p53 tumor and BTSC samples shows 
reciprocal changes in RNA level for the two genes. b, Representative image from RNA-FISH against 
Kcnq1ot1 RNA in tumor and BTSC samples, quantified in (c).  
 
Work in breast cancer cell lines has shown that transcriptional silencing of Cdkn1c can occur 
through multiple epigenetic mechanisms125. In order to parse the mechanisms by which silencing 
of the Cdkn1c promoter occurs, BTSC lines (n=6) were treated with the DNA methyltransferase 
inhibitor 5-Aza-deoxycytidine (5Aza) singly or in conjunction with the HDAC inhibitor 
Trichostatin A (TSA). We found that 5Aza treatment alone was able to reactivate Cdkn1c 
mRNA expression by more than 10-fold, while TSA treatment had no additive effect on 
transcription (Figure 3-5a). In addition, treatment of BTSC with 5Aza was found to abrogate 
self-renewal of tumor neurospheres in nanomolar concentrations (Figure 3-5b). Finally, we 
observed significant demethylation of the Cdkn1c gene locus in all treated BTSC lines by 
bisulfite-based mass spectrometry methylation assays (Figure 3-5c). Taken together, these 
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findings suggest that DNA methylation may be an important means of Cdkn1c regulation in 
BTSCs contributing to the maintenance of self-renewal.  
 
 
Figure 3-5 | Pharmacologic inhibition of DNA methylation in BTSC reduces self-renewal 
a, Inhibition of DNA methylation, but not histone deacetylation, reactivates Cdkn1c expression and leads 
to demethylation of the Cdkn1c promoter, shown in (c).  b, 5Aza treatment demonstrates dose-dependent 
decreases in self-renewal activity.  
 
Having characterized these molecular differences between the Ptc1;p53 BTSC and bulk 
compartments, we now sought to functionally investigate the role of Kcnq1ot1 expression in  
BTSC through lentiviral-mediated shRNA knockdown against Kcnq1ot1. Brain tumor stem cells 
were infected with empty vector, control hairpin (CTL-SH), or a hairpin targeted against the 
Kcnq1ot1 transcript (shLit1). Following selection, infected BTSC were plated at clonal density 
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to allow quantification of in vitro self-renewing capability. We observed a 75% decrease in self-
renewing neurospheres numbers as well as a 50% reduction in neurospheres size for shLit1-
infected cells compared to those with empty and control vectors (Figure 3-6a, b). Finally, the 
shLit1-treated BTSCs showed a nearly 10-fold reactivation of Cdkn1c expression (Figure 3-6c), 
comparable to the level of Cdkn1c expression we observed following pharmacologic inhibition 
of DNA methylation. While these observations have only been found in a single hairpin, these 
data potentially support a role for the long non-coding RNA Kcnq1ot1 in BTSC self-renewal 
through the modulation of Cdkn1c expression.  
 
 
Figure 3-6 | Kcnq1ot1 knockdown in BTSC leads to decreased self-renewal and proliferation 
a, Quantification from low-density self-renewal assay following lentiviral infection and knockdown. The 
average size of neurospheres observed was measured and shown in (b). c, Reactivation of Cdkn1c 
expression was observed in one of the hairpins utilized.  
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Discussion 
 
The key to creating novel and effective therapeutics for difficult to treat tumors revolves around 
developing an understanding of the molecules and pathways that make a particular tumor 
aggressive and refractory to therapy. Work by others in the field have shown that rare sub-
populations of stem-like cells may drive the most malignant disease and that clonal expansion of 
rare mutants within primary tumors may be underlying metastatic medulloblastoma87. As such, 
the intrinsic heterogeneity of the tumor and the lack of a good marker for prospectively isolating 
these cells have hampered their close investigation. Through our previous work, we have 
identified a unique population of brain tumor stem cells within Ptc1;p53 medulloblastoma and 
generated a highly purified and bioactive population through in vitro culture that represents an 
ideal system by which to characterize the differences separating the BTSC sub-compartments 
and the primary tumor from which they are derived.  
 
From a screen of 78 imprinted genes, we observed consistent and significant promoter 
methylation differences between the Ptc1;p53 primary tumors and the brain tumor stem cell lines, 
implying that distinct epigenetic states do exist between these two cell populations. In order to 
further characterize these observed differences, we focused on a set of coordinate changes 
between a known imprint control element, the long non-coding RNA, Kcnq1ot1, and one of its 
target genes, the cyclin-dependent kinase, Cdkn1c, for further study. Consistent with the 
occurrence of loss-of-imprinting at these loci in BTSC being functionally significant, we 
observed silencing of Cdkn1c expression concurrent with enrichment for bi-allelic expression of 
Kcnq1ot1, and reactivation of Cdkn1c expression as well as abrogation of self-renewal activity 
through inhibition of DNA methylation in the BTSC. These observations were further supported 
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by shRNA-mediated knockdown of Kcnq1ot1 associated with decreased self-renewal and 
proliferative capacity in the BTSC.  
 
Interestingly, while it is well known that Cdkn1c plays a role in progenitor maintenance in other 
organ systems120,126 and even within some populations of neural progenitors122, its role in 
cerebellar development and differentiation, if any, is largely uncharacterized. Indeed, of the 
many cyclin dependent kinases, only p21 and p27 have been reported to be significantly 
expressed in the developing cerebellum127. Specifically, p27 has been shown to be involved in 
controlling GCP proliferation and in suppressing medulloblastoma formation in a mouse 
model128. Given that the Ptc1;p53 BTSCs express markers of both cerebellar stem cells and 
granule cell progenitors, we speculate that modulation and silencing of Cdkn1c expression may 
represent a novel mechanism by which these cells are able to resist normal cues for 
differentiation and aberrantly persist to form tumors with stem-like characteristics. 
 
Finally, non-coding RNAs such as microRNAs have been widely implicated in maintaining 
neural stem and progenitor populations129, and specifically in modulating Shh signaling in 
cerebellar progenitors as well as in driving malignant progression130. However, the role of long 
non-coding RNAs in modulating neural progenitor differentiation and maintenance is as yet 
undefined. To our knowledge, this work represents the first report to implicate the activity of a 
long non-coding RNA in modulating neural stem cell self-renewal. Thus, the careful 
characterization of the roles of Kcnq1ot1 and Cdkn1c within the context of malignant BTSCs as 
well as normal cerebellum merits further investigation and consideration.   
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Methods 
 
Neurosphere culture, Low-density neurosphere formation and clonogenicity assays  
293T culture- Human 293T cells were maintained adherently in DMEM supplemented with 10% 
Cosmic calf serum (Gibco). Passaging was carried out through trypsinization, trituration, and re-
plating of cells.  
 
Bulk cultures- Tissues were isolated, minced, and triturated in Accutase (Millipore) to obtain a 
single cell suspension. After centrifuging, cells were grown in neurosphere (NS) media 
consisting of DMEM/F12 supplemented with 20ng/ml of bFGF, 20ng/ml of EGF, B27 
supplement, and penicillin/streptomycin109. Bulk neurosphere cultures were passaged by 
disaggregation with Accutase and maintained in NS media.  
 
Clonal analyses- To quantify self-renewal, neurospheres were dissociated into single cells using 
Accutase, counted, and plated at 1500 cells/ml in NS media in six-well replicates. Clonal 
neurospheres were counted after two weeks. For the 96-well clonogenicity assays, limiting 
dilutions of cells were plated in replicate wells in a 96 well plate in 100µl of NS media per well. 
Wells were scored for the presence of neurospheres and the frequency of positive wells used to 
calculate the frequency of self-renewing cells using the Poisson distribution110. 
 
Generation of short hairpin RNAs 
Briefly, short hairpin RNA sequences targeted against Kcnq1ot1 were generated using 
pSicoOligoMaker 1.5 software as well as the DSIR algorithm131 
(http://biodev.extra.cea.fr/DSIR/DSIR.html), and cloned into the pSicoR-puro vector, a modified 
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pSicoR vector that was originally a gift from Dr. Tyler Jacks (Whitehead Institute, MIT), 
allowing puromycin selection following infection via established protocol. Selected sequences 
were screened through the NCBI-BLAST software to minimize off-targeting and ligated DNA 
colonies were screened for hairpin insertion by a PCR assay and sequenced for validation. 
Validated clones were grown up and plasmid DNA was isolated via Midi-prep columns (Qiagen) 
for lentiviral transfections.  
 
Lentivirus production and infection 
293T cells were plated onto gelatinized 10cm tissue culture dishes at ~30% confluency the day 
prior to transfection. Calcium phosphate transfection was performed using 15ug of the pSicoR-
Puro-shRNA vectors, 10ug PAX packaging vector, and 5ug VSV lentiviral vector in 10mL of 
fresh media. Sixteen hours following transfection, the 293T media was changed to NS media and 
viral supernatants harvested 48 hrs following transfection. To infect BTSC, ~106 dissociated cells 
were spun-down and re-suspended with 2ml of viral supernatant supplemented with 10ug/ml 
polybrene in 6-well plates. Plates were spun at 2000 rpm for 45 minutes. Cells were 
subsequently collected, spun down, and resuspended in fresh NSM. Puromycin selection was 
begun 24 hours post-infection and maintained for 2 days in order to enrich for infected cells.  
 
Quantitative RNA expression analyses 
Total RNA were prepared from primary tissue and neurospheres cultures using RNA Mini Spin 
columns (Qiagen) and converted to cDNA using the ABI high-capacity cDNA reverse 
transcription kit. Expression values were calculated by delta-deltaCt method and normalized to 
Gapdh. Primers were as follow:  
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Gapdh:  5'- GTTGTCTCCTGCGACTTCA -3', 5’- TGGTCCAGGGTTTCTTACTC -3' 
Lit1:  5'- GGCAGGCAGGATTAACCAGAT -3',  
5'- AGAACTATAATCAAGCAATCCAATCCTT -3' 
p57: 5’- GAAGAAGTCGTTCGCATTGGC -3’, 5’-CGAGGAGCAGGACGAGAATC -3’ 
 
Bisulfite-based mass spectrometry methylation assay 
For methylation assays, genomic DNA from tissue and BTSC lines were isolated using standard 
isopropanol precipitation and purified by phenol-chloroform extraction. Quantitative methylation 
analyses were performed on the MassArray EpiTYPER platform (Sequenom, San Diego)118. 
Briefly, sodium bisulfite treated DNA is transcribed in vitro, subjected to base-specific cleavage, 
and analyzed by MALDI-TOF MS. PCR amplicons were designed to cover CpG islands and 5' 
promoter regions of selected genes.  
 
RNA fluorescence in situ hybridization (RNA-FISH) 
Briefly, single cell suspensions were created from BTSC cultures and primary tumor samples. 
Cells were fixed with 4% PFA, permeabilized with 0.5% Triton in DEPC-PBS, and plated onto 
glass slides. Probe hybridization and subsequent procedures were performed as described by Q. 
Wang (personal communication) and Mohammad et al132. Plasmid with the Lit1-probe was a 
generous gift from Dr. M. J. Higgins (Roswell Park Cancer Center, Buffalo, NY).  
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Chapter 4 Perspectives and Future Directions 
“Down to their innate molecular core, cancer cells are hyperactive, survival-endowed, 
scrappy, fecund, inventive copies of ourselves.” 
-- Siddhartha Mukherjee133 
 
Whether it occurs in adults or children, cancer is fundamentally a developmental disease that is 
marked by deregulation of critical developmental pathways134. As such, the characterization and 
study of processes critical for tumorigenesis and normal developed are intertwined. While the 
advent of high-throughput tools for analyzing the genetic landscape of large cohorts of tumors 
has allowed us to look ever deeper into tumors and identify the slightest of differences, the 
challenge now arises in distinguishing the meaningful driver mutations from those that are not 
and functionally characterizing those changes to understand the underlying tumor biology. In this, 
the investigation of pediatric malignancies such as medulloblastoma may prove particularly 
rewarding as they generally contain fewer genomic changes than adult malignancies76 and thus 
may more clearly highlight the important pathways and processes involved in development and 
tumorigenesis.  
 
It has been this sense of discovery and wonder in attempting to study and understand the delicate 
balance between normal development and progression to malignancy that has fascinated me the 
most in the last few years and that will continue to drive my work in the future. What follows is 
an overview of my ongoing efforts as well as some of my personal thoughts on the significance 
of my contributions while part of the Jackson-Grusby lab.   
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Insights from mouse medulloblastoma models into human disease 
The use of mouse models has been integral in furthering our understanding of the developmental 
bases and cellular origins of medulloblastoma formation. Integrated genomic approaches have 
allowed the division of medulloblastomas into four different subgroups that differ in terms of age 
of incidence, tumor histology, gene expression, and prognoses. Interestingly, SHH-type tumors 
occur in a bimodal age distribution: primarily either before 3 years or after 15 years of age2. 
Furthermore, molecular characterization of these early and late occurring SHH-type tumors have 
shown them to be clinically, transcriptionally, and prognostically distinct135 although the 
biological mechanisms driving the formation of the earlier tumor-type remain to be clearly 
elucidated. Given that the addition of a p53-mutation dramatically increases medulloblastoma 
incidence and accelerates tumor formation34, comparisons of the Ptc1 and Ptc1;p53 mouse 
medulloblastoma models may provide some initial insight into these differences (Figure 4-1).  
 
Figure 4-1 | Ptc1 and Ptc1;p53 medulloblastoma are developmentally and functionally distinct 
Schematic illustrating the key differences distinguishing Ptc1 and Ptc1;p53 medulloblastoma. Namely, 
the complete colonization of the developing cerebellum by the Ptc1;p53 genotype leading to the aberrant 
persistence of a population of self-renewing cells that go on to form metastatic tumors with stem-like 
characteristics.  
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We have observed that Ptc1;p53 and Ptc1 represent functionally distinct tumor types and 
implicated that p53 may be involved in altering the characteristic of the developing tumor. 
Consistent with our findings, studies of human tumor samples have shown that patients with 
Gorlin’s syndrome, associated with SHH-deregulation, tend to have a tumor histology 
characterized by extensive nodularity whereas Li-Fraumeni patients carrying mutations germ-
line p53 mutations develop medulloblastomas with a classic histology136. More generally, 
histological studies of human medulloblastoma tumors carrying somatic mutations in p53 only 
very rarely have desmoplastic histology: even the SHH-subtype tumors exhibit classic tumor 
histology in the context of p53 mutations137.  
 
The biological mechanisms by which loss of p53 may alter tumor kinetics and properties has 
been largely attributed to p53-loss triggering extensive and maladaptive DNA rearrangements138. 
By studying the influence of p53 mutation within a developmental context, our work has 
suggested that p53 loss additionally allows the formation of an aberrant self-renewing population 
of tumor-initiating cells. Work by the Wechsler-Reya group have utilized a conditional Ptc1-
deletion model to demonstrate that a) expansion of a granule cell progenitor is necessary for 
tumor-formation and b) Ptc1 LOH must occur prior to postnatal day 10 in order to allow 
tumorigenesis. Our observation that that the Ptc1;p53 but not the Ptc1 genotype results in 
aberrantly self-renewing neurospheres is consistent with not only an expansion of the population 
of potential tumor-initiating cells but also a widening of the susceptible time-window in which 
Ptc1 LOH must occur in order to facilitate tumorigenesis in a manner dependent on loss of p53.  
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Although p53 has been shown to be involved in adult neural and brain tumor stem cell self-
renewal56,57, the mechanism by which this may occur has been unclear. Indeed, while direct p53 
mutations are only rarely found in human medulloblastoma35, alterations in p53 modulation 
within these tumors is becoming increasingly appreciated39,40,57. Using Sox2-GFP fractionation 
within the context of the wild-type developing cerebellum we have been able to appreciate gene 
expressions changes consistent with Id2 modulation of p53 activity representing a potential axis 
by which p53 could be involved in modulation of stem-cell progenitor pool size (Figure 2-18). It 
is notable that the Northcott study characterizing differences between early and late-occurring 
SHH-type medulloblastomas identified Id2 as one of the most differentially expressed genes 
found in the early-onset tumors135, consistent with Ptc1 and Ptc1;p53 tumors functionally distinct 
and suggesting that alterations in cerebellar stem cell differentiation mediated by p53 may play a 
significant role in determining the properties of these more aggressive and disseminated tumors.  
 
The role of cerebellar stem cells in medulloblastoma  
When I first began work in the Jackson-Grusby lab, the idea of a cancer stem cell existing within 
medulloblastoma was still an emerging concept58. At the time, the mechanisms and gene 
pathways responsible for driving their formation and maintenance were just beginning to be 
elucidated. The granular cell progenitor was already a well-characterized and accepted cell of 
origin for Shh-type medulloblastoma formation but was not thought to be at the root of the other 
types of medulloblastoma66,90(Figure 4-2). While it is now known that a self-renewing, 
multipotential stem cell exists in the normal as well as malignant cerebellum58 and that isolated 
cerebellar stem cells can indeed be induced to form tumors68,70, neither the developmental origin 
of this cell nor the endogenous mechanism of transformation has yet been carefully defined.  
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The observation of expression of cerebellar stem as well as granular progenitor markers in the 
clonal Ptc1;p53 BTSC lines suggests either transformation-associated blurring of the distinction 
between CbSC and GCP or the existence of a common progenitor cell that may possess both 
Shh-dependent and independent characteristics. Indeed, a recent study has reported that 
transduction of mutant MYCN into embryonic and postnatal cerebellar stem cells led to the 
development of Shh-dependent and independent tumors, respectively139. The validation of Sox2 
as a definitive marker for self-renewing cerebellar stem cells using the Sox2-GFP reporter 
animal98,99 provides a particularly tractable model in which to further characterize the cerebellar 
stem cells within the context of both normal and malignant development. While 
immunohistochemical staining for Sox2 in both the adult mouse68 and human cerebella101 has 
marked isolated cells within the cerebellar white matter as well as the Bergmann glia in the 
Purkinje cell layer, the developmental potency of Sox2-expressing cerebellar cells has yet to be 
characterized. I have been working to address this question through an ongoing collaboration 
with the Hochedlinger lab to perform cerebellar lineage-tracing experiments utilizing their Sox2-
CreER;ROSA26-Isl-EYFP mice98. By initiating tamoxifen-induced recombination in the early 
postnatal cerebellum, we are hoping to directly assay the developmental potency of the early 
Sox2-positive cells within the endogenous wild-type context.  
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Figure 4-2 | Sox2+ cerebellar stem cells as an alternative medulloblastoma cells of origin 
Schematic illustrating the two stem and progenitor cell populations known to be present within the 
developing cerebellum: bFGF/EGF-dependent Sox2-positive cerebellar stem cells and the SHH-
dependent Math1-positive granular cell progenitors.  
 
In order to extend our observations to the mouse tumor models, I have obtained the Sox2-GFP 
and Sox2-CreER targeting constructs from the Hochedlinger Lab and modified them for use 
within our mutant embryonic stem cell lines. Having successfully generated targeted 
Ptc1;p53;Sox2-GFP ES lines, we are currently in the process of producing chimeric 
medulloblastoma reporter mice. With these animals, we will be able to determine the anatomic 
origins of the Sox2-positive cells in the developing pre-malignant as well as tumor-bearing 
cerebellum. Comparisons with the wild-type reporter animals will allow us to identify the origin 
of these aberrant self-renewing cells. Consistent with our observed lack of self-renewal in the 
wild-type mature cerebellum, preliminary flow cytometric studies I performed examining a 
cohort of wild-type reporter animals show a complete lack of identifiable GFP-positive cells in 
the 3-week cerebellum (data not shown). By contrast, 3-week Ptc1;p53;Sox2-GFP chimeric 
animals show the continued persistence of a distinct population of GFP-positive cells that 
constitute approximately 10% of the total cerebellum (data not shown). Continued molecular 
characterization of these cells for gene expression as well as assaying for Ptc1-LOH will be 
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revealing to see if we are able to capture the earliest cells with tumor-initiating capabilities well 
prior to overt tumorigenesis. 
 
Furthermore, given that we have already observed gene expression differences following in vitro 
culture, I expect that the use of the Sox2-GFP reporter system will additionally facilitate the 
prospective marking and isolation of the self-renewing, tumor-initiating cells directly from the 
primary tissue and allow us to more closely examine the in vivo state of these cells through gene 
expression analyses. In this regard, given that I observed significantly increased numbers of 
CD15- and CD133-marked cells in the Sox2-positive fraction, we will investigate whether 
sorting for CD15/CD133/Sox2 triple-positive cells will further enrich for the bio-active 
population of cells. I have previously seen that direct injection of 5x104 unfractionated Ptc1;p53 
primary tumor cells gives rise to cerebellar tumors over a period between 5 and 10 weeks and am 
interested to see how enrichment for these self-renewing cells may increase tumorigenic 
potential.  
 
While there are a number of clinical studies for medulloblastoma focused on using SHH-
pathway antagonists as single-agent treatment protocols, I hope that the work presented here 
taken in conjunction with the increasing appreciation throughout the field of both inter- and 
intra-tumor heterogeneity will cause us to design and develop multi-pronged therapeutic 
approaches that will simultaneously target multiple aspects of tumor cell biology. Specifically, 
the observation that while treatment with SHH-antagonists in both mice43,45 and human44 
medulloblastoma may delay tumor progression, it is not, in most cases, curative.  The 
appreciation and further characterization of a Sox2-positive bFGF/EGF-dependent cell of origin 
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for medulloblastoma through the use of GFP-reporter system ,will allow the elucidation of novel 
pathways that will hopefully contribute to the development of new treatment paradigms for Shh-
subtype tumors. 
  
Finally, our work in characterizing the epigenetic state of the Ptc1;p53 BTSC has identified a 
potentially promising and novel mechanism by which BTSC are able to resist differentiation. I 
have generated four new lentiviral hairpins targeted against the Kcnq1ot1 RNA to further 
substantiate the role of Kcnq1ot1-mediated regulation of Cdkn1c in maintenance of BTSC self-
renewal. The parallel use of the Sox2-GFP system here will allow us to ask if bi-allelic 
expression of the Kcnq1ot1 locus can be directly observed in the self-renewing cells of the 
developing and tumor-bearing cerebellum. Lastly, the ability to isolate highly pure populations 
of cerebellar stem cells from both wild-type and mutant animals opens the door for high-
throughput screens that will allow us to compare the genetic and epigenetic states of these cells 
and gain insight into the genes and pathways involved in modulating their existence.  
 
Developmental field cancerization and human malignancies 
In its initial description by Slaughter92, the phenomena of field cancerization was observed in 
epithelial malignancies wherein predisposing mutations, often associated with p53, conferred a 
growth advantage to those cells allowing the out-competition of wild-type cells in the field and 
facilitating the formation of a ‘patch’ or ‘field’ of pre-malignant cells that could subsequently 
give rise to malignancy. Within this framework, field cancerization preceding malignant 
transformation has been used to describe tumors associated with, but not limited to, Barrett’s 
esophagus secondary to acid-reflux140, multifocal and recurrent squamous cell cancers of the 
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upper aerodigestive tract in the context of tobacco-use and other carcinogens141, hepatocellular 
carcinoma occurring secondary to hepatitis-infection142, ulcerative colitis associated neoplasia143, 
and gastrointestinal cancers arising in the context of Helicobacter pylori infection144. As thus 
conceptualized, properties considered for the occurrence of field cancerization may consist of a 
tissue system that undergoes continuous cellular turn-over as well as an ongoing source of 
external insult or cellular injury that may be facilitating the accumulation of stochastic mutation 
or cellular turn-over, respectively.  
 
The choice of using a somatic mosaic model for studying medulloblastoma formation allowed us 
to make a serendipitous observation that would not have been otherwise possible: Ptc1;p53 cells 
are able to non-randomly and preferentially seed the developing cerebellum such that nearly 
100% of the chimeric animals developed medulloblastomas. In observing the dramatic and 
specific pre-malignant seeding of cerebellar field prior to tumorigenesis, we are seeing a tissue-
specific competitive growth advantage for the Ptc1;p53 mutant cells which we have been able to 
attribute to Ptc1 haploinsufficiency. Thus, the first hit of the Ptc1 gene has, contrary to 
Knudson’s two-hit hypothesis106, not a neutral, but a very significant influence on future disease 
susceptibility. More broadly, these observations suggest that germ-line inheritance of tumor 
suppressor genes does not have to occur in order to pre-dispose an individual to future 
malignancy. More generally, we have been able to re-frame field cancerization within a 
developmental context characterized by wide-spread and rapid cellular proliferation, 
differentiation, and turnover, and illustrate how preferential dependence on a given morphogen 
tumor suppressor pathway in particular organ systems may confer profound influence to 
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corresponding de novo tumor suppressor gene mutations occurring during early embryonic and 
organismal development. 
 
These conclusions naturally bring to mind the observations that mutations in some widely 
expressed tumor suppressor genes are associated with characteristic tumor spectra: Rb mutations 
with retinoblastoma, BRCA with breast and ovarian cancers, NF1 with neurofibromatosis-1, APC 
with colon cancer, etc145. One would expect that analogous experiments performed with mouse 
ES cells heterozygous for tumor suppressor genes other than Ptc1 would exhibit preferential and 
distinct tissue colonization reflective of the expected tumor spectra for a given gene mutation. 
For instance, the developmental expression of the BRCA genes is consistent with their playing a 
critical role in the differentiation of breast epithelia146,147 and is further substantiated by 
observations that BRCA1 depletion by RNAi leads to impaired differentiation and enhanced 
proliferation of breast epithelial cells148.  
 
If developmental field cancerization were more broadly applicable, it could influence the 
framework in which we conceptualize tumorigenesis. Up until now, tumor evolution has been 
primarily modeled by the accumulation of mutations within small cell populations through 
progressive Darwinian selection149.  However, most models are not able to reconcile differences 
between the number of mutations thought to be needed for tumor progression and the 
spontaneous mutation rate of normal cells, and thus posit that acquisition of a ‘mutator 
phenotype’ or genetic instability is necessary for multistage tumorigenesis150. Computation work 
modeling the dynamics of tumor suppressor gene inactivation has suggested that with extremely 
large starting populations, the waiting time prior to complete tumor suppressor gene activation 
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becomes exceedingly short151. Developmental field cancerization could allow for the generation 
of just such a large population from an otherwise ‘neutral’ tumor suppressor gene mutation, 
allowing for unhindered expansion of the pre-malignant field. In this context, Ptc1-
haploinsufficiency mediated colonization of the cerebellum in medulloblastoma formation 
involves potentially 25-30 million granular neurons in mice152 ; the susceptible cerebellar field in 
humans is thought to include approximately 50 billion granular neurons153.  
 
Within humans, evidence for significant somatic mosaicism has already been reported in 
retinoblastoma154 as well as neurofibromatosis patients155. 
Given our ever-increasing ability to differentiate between normal and tumor tissue on a genetic 
level, it is my belief that the observation of developmental field cancerization in humans is 
imminently possible.  
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